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Nuc = C, S, N
ABSTRACT: Herein we report our full investigation into the calcium catalyzed generation and trapping of N-acyliminium ions from 
readily available 3-hydroxyisoindolinones. We have successfully employed a range of traditional nucleophiles including  carbon, 
nitrogen and sulfur containing reactive partners. The reaction is tolerant to a wide range of functionalities and provides high value 
scaffolds in good to excellent yields.  
INTRODUCTION
N-acyliminium ions represent a highly useful reactive
intermediate that has found use in a plethora of synthetic
methodologies and total synthesis alike.1-2 Over the course of
several decades, these reactive intermediates have been
employed to form new carbon-carbon and carbon-heteroatom
bonds with great success. In particular, N-acyliminium ions
have shown utility in the synthesis of fused ring systems
through intramolecular trapping of the generated reactive
intermediate.3-6 This strategy has been thoroughly explored over
the last two decades with noted examples such as in the total
syntheses of stemoamide,7 crispine A,8 and minfiensine (Fig
1).9
Traditionally, N-acyliminium ions are generated via the 
activation and release of a suitable leaving group under acidic 
conditions. There is a wide range of these suitable leaving 
groups including hydroxyl,10 alkyl- and aryloxy,11 acetoxy12-13 
and carbamate,14-15 however sulfur containing and sulfoxide 
based groups have also found use.16 As the synthetic utility of 
these intermediates becomes more obvious, the need to generate 
them using more functionally tolerant reagents remains high. 
Success using stoichiometric Lewis acids such as BF3.OEt2,17 
Sc(OTf)3,18 TiCl4,19 and AlCl320 have all recently been reported. 
Furthermore, organic acids such as p-TsOH and TFA have also 
been shown to generate N-acyliminium ions efficiently under 
notably milder conditions.21 Although great successes have 
been described employing stoichiometric reagents, there is a 
clear need to develop catalytic processes by which these 
important intermediates can be generated. This need is twofold; 
firstly, catalytic generation inherently produces less waste, with 
the byproducts using hydroxyl or akyloxy leaving groups being 
water or innocuous alcohols. Secondly, from a reactivity point 
of view, catalytic generation will result in a more controlled 
reaction profile, with a much-reduced propensity for side 
reactions. Unsurprisingly, there has been noted successes in this 
endeavor (Scheme 1), with elegant examples using Brønsted 
acids,22-24 thiourea organocatalysts25-28 and Lewis acids.29-33  






































Scheme 1 .Strategies towards N-acyliminium Ions





























































Other methods including protonation of enamides34 and anodic 
(Shono)oxidation35 have also been described with varying 
success 
Our group has a growing interest in developing methodology to 
catalytically generate reactive intermediates,36 and in particular 
using calcium complexes to mediate these processes.37-38 
Calcium represents a relatively underexplored metal in 
catalysis,39 however over the past decade there has  been an 
icrease in interest in exploring the reactivity of calcium, which 
has resulted in a wealth of innovative uses for this abundant 
element.40-60 We,37 and others,61 have recently reported the use 
of Ca(NTf2)2 as an excellent catalyst to produce N-acyliminium 
ions from readily available 3-hydroxyisoindolinones. Due to the 
importance of these scaffolds in both total synthesis62-64 and 
medicinal chemistry,65 we wanted to explore this reaction 
further. In particular, we set out to probe the limits of the 
reaction towards traditional carbon, amine and sulfur 
nucleophiles. In particular, we wanted to focus our attention on 
the synthesis of functionalized isoindolinones, due to their 
importance in an ongoing medicinal chemistry campaign within 
our group. Unsurprisingly, due to their range of interesting 
biological activities,66-68 the synthesis of these scaffolds has 
attracted much attention in the literature (Scheme 2). In 
particular, the use of Brønsted and Lewis acids catalysts have 
been shown to be well tolerated. Although these examples 
provide the desired products in typically good yields, the use of 
tertiary hydroxyisoindolinones remains underexplored. This 
somewhat limits the use of the more complex catalytic systems, 
as it results in less than optimum substrate availability. Thus we 
wanted to explore these tertiary alcohols, and to probe the limits 
of the reactions.
RESULTS AND DISCUSSION
We began our investigation employing indoles as nucleophiles. 
We rationalized that due to its importance in medicinal 
chemistry, paired with the availability of the motif, we could 
provide high value scaffolds bearing pendant functional groups 
in a controlled and high yielding manner. Furthermore, due to 
the ubiquitous nature of functionalized indoles in natural 
products, functionally tolerant catalytic methods to afford these 
types of compounds are constantly required. Indeed, upon 
treating 3-hydroxyisoindolinone with 10 mol% Ca(NTf2)2 -
/nBu4NPF6 in the presence of 5-bromoindole, the desired 
product was formed in high yield (83%). Reducing the catalyst 
loading to 1 mol% had little effect on the reaction, providing 
the product in identical yield. Further optimization including 
varying the solvent, temperature and concentration had a 
deleterious effect on the yield of the reaction (Table 1). Finally, 
lowering the catalyst loading to below 1 mol% resulted in a 
noticeably more sluggish reaction, and we decided that in the 
interest between balancing catalyst loading and reaction time, 1 
mol% was optimum. Importantly, we also performed a series of 
control experiments, most notable of which was using 2,6-
ditertbutylpyridine (entry 9), a known inhibitor of Brønsted 
acid catalysis. The reaction proceeded unhindered, and proves 



































































a Isolated Yield b 2,6-ditertbutylpyridine added
Table 1. Optimization study
With these conditions in hand we probed the substrate scope of 
the reaction (Scheme 3). We observed excellent conversion to 
the products in all cases, providing a wide variety of complex 
scaffolds quickly. As shown, the reaction is tolerant to 5-bromo 
and 5-pinacolboronate indoles, affording a range of highly 
useful building blocks, including electron electron-withdrawing 
(3b) and donating groups (3c, 3h) as well as further heterocyclic 
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Scheme 3. Indole Substituted Isoindolinones
Scheme 2. Recent Successes in N-acyliminium chemistry






























































As many catalytic processes are tolerant to carbon based 
functional groups, but show limited reactivity when 
heterocyclic reaction partners are used, we wanted explore the 
limits of the calcium system to these coupling partners. We 
decided to therefore move onto sulfur containing fragments, 
and in particular, aromatic and aliphatic thiols. N(acyl),S-
acetals are found in numerous pharmacologically relevant 
natural products and APIs alike. The most well-known of these 
being -lactam antibiotics69 and HIV-1 Reverse Transcriptase 
inhibitors.67 Several methods have been developed for their 
synthesis, including a range of Brønsted acid catalyzed 
transformations,70 however they typically require long reaction 
times and showed a limited scope towards certain functional 
groups. We reasoned that the use of calcium to mediate these 
reactions would have several advantages including much 
shorter reaction times, a wider functional group tolerance and 
overall easier reaction set up i.e. no requirement for anhydrous 
or air free condition. Traditionally, it would be expected that 
that the nucleophilic nature of these species would poison the 
catalyst, or at the very least, drastically hinder the catalytic 
turnover. However, to our delight, we found that the reaction 
using thiophenol proceeded well, with the reaction complete in 
under 15 minutes. Once again, we probed the substrate scope of 
the reaction, and a range of substituted hydroxyisoindolinones 
were subjected to our reaction conditions, resulting in a library 
of 3,3-disubstituted lactams (Scheme 4). As shown, the reaction 
was again tolerant of a range of functional groups with electron 
donating (4a-b) and withdrawing groups (4c-e) providing the 
desired products in high yields. Phenyl ring substituents was 
also well tolerated, with ortho and meta substituents proceeding 
smoothly (4f-g). Finally, heterocyclic substrates also worked 
well, providing the lactam products in high yields (4h-j).  
As these examples all employed thiophenol as a nucleophile, 
we wanted to explore the tolerance of other sulfur derivatives. 
Once again, the reaction proceeded well, providing a wide range 
of medicinally relevant scaffolds (Scheme 5). In addition to the 
traditional electron donating (6a, 6d, 6e) and withdrawing (6b, 
6c) groups, heteroaryl (6f, 6g), benzyl (6h) and alkyl (6i, 6j) 
substituents all worked well. Furthermore, boronate esters (6k) 
are also well tolerated, providing avenues for the modular 
synthesis of bioactive small molecules. 
We next turned our attention to amine nucleophiles, as we 
envisaged that they would be more problematic in the reaction, 
mainly through direct Lewis acid-Lewis base interactions. 
Additionally, in contrast to their sulfur counterparts, 3-
aminoisoindolinones are relatively underexplored in synthesis, 
with very few reports focusing on the synthesis of carbamate 
and sulfonamide derivatives. This is somewhat surprising, 
given the fact that many isoindolinones have exhibited marked 
activity against a range of bacterial infections71-72 as well as 
interesting anticancer properties.68 Due to this, we initially 
focused on delivering a robust method to produce these 
potentially high value molecules from readily available starting 
materials. We started our investigation employing our 
optimized conditions and simple amine nucleophiles (Scheme 
6). We observed a clear trend in reactivity, in which only 
electron withdrawing anilines were tolerated, however we could 
never manage to isolate the products in useful yields. 
Additionally, the reaction was highly variable, and in our hands, 
remained unreproducible. On the small amount of material we 
did isolate, we observed a rapid degradation profile, with 
complete degradation after 2 hours, regardless of storage 
temperature.  After some investigation, that the reaction 
employing N-Bn substituted hydroxyisoindolinones were much 
more user friendly, reproducibly providing the desired product 
in good yield. As shown, the reaction proceeded well, with 
substrates bearing contrasting electronics (8a-c) being 
























































R1 SCa(NTf2)2 (1 mol%)
nBu4NPF6 (1 mol%)




4a, 77% 4b, 86% 4c, 86%
4d, 79% 4e, 96% 4f, 84%
















































R1 SCa(NTf2)2 (1 mol%)
nBu4NPF6 (1 mol%)









6h, 92% 6i, 91%
6j, 93% 6k, 74%
5
Scheme 4. Thiophenol substrate scope
Scheme 5. Scope of Sulfur Nucleophiles





























































Once complete, we probed the applicability of using less 
nucleophilic amine sources, such as the previously mentioned 
amide and sulfonamide moieties. Once again employing our 
optimized conditions, and using 1a as our model substrate, we 
screened a range of carbamate nucleophiles. Unfortunately, all 
of these proved unsuccessful, with the reactions plateauing at 
25% conversion (Scheme 7). 
After extensive experimentation in which we screened a wide 
range of conditions including solvent, temperature, time and 
nucleophile, we were unsuccessful in delivering a reliable 
reaction that produced these compounds in synthetically useful 
yields. Although unsuccessful for compounds such as 1a, we 
were successful in performing the reaction on 11 using a small 
range of carbamate and amide nucleophiles, as shown (Scheme 
8). This provides a range of differentially protected amines 
(12a-12c), which has the potential to find use in target 
synthesis.
Due to the limited scope of these carbamates, we moved our 
attention to the more useful sulfonamides. Once again these 
have been seemingly ignored by the synthetic community, and 
therefore provides potentially new avenues of biological 
activities to be uncovered. The reactivity pattern remained, with 
only unsubstituted 11, providing reproducible reactivity and 
good yields throughout. Probing the variability of the 
sulfonamides produced a range of useful scaffolds using 5 
mol% of the catalyst system. As shown above (Scheme9), the 
reaction was once again tolerant to a range of synthetically 
useful functional groups including electron donating (14a, 14b) 
withdrawing (14c) halides (14d-f) thiophene (14g). 
Furthermore, saturated groups (14h) also worked well, 
providing access to 3-dimensional scaffolds.
As observed, the reaction is generally tolerant to a wide range 
of functional groups and nucleophiles. However, during the 
course of this work, we noted some limitations which we 
believe the community will find useful when deciding to use 
this methodology. Firstly, when employing  amine 
nucleophiles, the reactions were very sluggish with tertiary 
alcohols such as 1a, with many reactions not going to 
completion. This was consistent across all amine nucleophiles 
used in this study. In a similar vein, we also observed that the 
choice of amine was important, with secondary amines such as 
piperidine and morpholine providing variable reactivity 
patterns, with irreproducible results being obtained. Secondly, 
carbon based nucleophiles (outside indole and allylsilane) were 
unreactive towards the conditions described here. We are 
currently working on this, and hope to report on it soon.  
A proposed general mechanism is provided below (Fig. 2). The 
postulated active catalyst, [CaPF6NTf2] A, is formed between 
Ca(NTf2)2 and nBu4NPF6 which in turn produces N-
acyliminium ion B and complex C via loss of the non-
coordinating PF6 ligand. Following nucleophilic attack, the 
aforementioned displaced PF6 re-enters the cycle, providing the 
































































































































































14a, 85% 14b, 91% 14c, 68%
14d, 75% 14e, 75% 14f, 60%
Ca(NTf2)2 (5 mol%)
nBu4NPF6 (5 mol%)
1,2-DCE, 80 oC, 12 hrs
14g, 77% 14h, 61%
11 1413
Scheme 6. 3-Amino substituted isoindolinones
Scheme 7. Reaction with Benzylcarbamate
Scheme 8. Carbamate and amide substitution reactions
Scheme 9. Functionalized isoindolinones bearing 
pendant sulfonamides






















































































Figure 2. Proposed general catalytic cycle
In conclusion, we have developed a robust and high yield 
methodology to afford a range of substituted isoindolinones. 
Using low loadings of catalyst, the reaction proceeded 
smoothly, with reaction times ranging from 15 minutes to 12 
hours. The reaction is tolerant towards a series of traditional 
nucleophiles including carbon, nitrogen and sulfur containing 
moieties. We envisage that this methodology will find use 
within medicinal chemistry campaigns due to the range of 
biological activities these scaffolds have shown.
EXPERIMENTAL SECTION
Solvents and Reagents. All solvents were purchased from 
commercial sources and used without purification (HPLC or 
analytical grade). Anhydrous solvent was obtained from a The 
Solv™ Solvent Purification System. Standard vacuum line 
techniques were used and glassware was oven dried prior to use. 
Organic solvents were dried during workup using anhydrous 
Na2SO4. All calcium catalyzed reactions where done without 
the need for anhydrous or air free conditions. All reaction were 
performed using DrySyn™ heating mantles and pressure 
regulated vials.
Purification and chromatography. Thin Layer 
Chromatography (TLC) was carried out using aluminum plates 
coated with 60 F254 silica gel. Plates were visualized using UV 
light (254 or 365 nm) or staining with 1% aq. KMnO4, vanillin 
or ninhydrin. Normal-phase silica gel chromatography was 
carried out using either a Biotage Isolera One flash column 
chromatography system (LPLC) or traditional flash column 
chromatography using Geduran® Silica gel 60, 40–63 microns 
RE. 
Characterization. Infrared spectroscopy was carried out with 
a Nicolet® 380 FT/IR – Fourier Transform Infrared 
Spectrometer. Only the most significant frequencies have been 
considered during the characterization and selected absorption 
maxima (max) recorded in wavenumbers (cm-1). NMR spectra 
were recorded using a JEOL® ECS-400 MHz spectrometer 
using the deuterated solvent stated. Chemical shifts (δ) quoted 
in parts per million (ppm) and referenced to the residual solvent 
peak. Multiplicities are denoted as s- singlet, d- doublet, t- 
triplet, q- quartet and quin- quintet and derivatives thereof (br 
denotes a broad resonance peak). Coupling constants recorded 
as Hz and round to the nearest 0.1 Hz. High Resolution Mass 
Spectrometry (HRMS) was recorded using an Agilent 
Technologies® 6540 Ultra-High-Definition (UHD) 
AccurateMass equipped with a time of flight (Q-TOF) analyzer 
and the samples were ionized by ESI techniques and introduced 
through a high pressure liquid chromatography (HPLC) model 
Agilent Technologies® 1260 Infinity Quaternary LC system. 
3-(5-bromo-1H-indol-3-yl)-3-phenyl-2,3-dihydro-1H-isoindol-
1-one (3a). To a 4 mL vial was added 3-hydroxy-3-
phenylisoindolin-1-one (50 mg, 0.22 mmol), Ca(NTf2)2 (1.3
mg, 0.0022 mmol) and nBu4NPF6 (1 mg, 0.0022 mmol) in DCE 
(1 mL) at 80 ºC. The reaction was stirred for 1 minute and 5-
bromoindole (65 mg, 0.33 mmol) was added in a single portion 
and stirred at 80 ºC for 15 minutes. Once TLC analysis indicated 
conversion to the product, the product was concentrated and 
purified by flash column chromatography (3:1 EtOAc:Hex) to 
afford a cream solid (73 mg, 82%). RF (3:1 EtOAc/Hex) = 0.37. 
IR νmax (cm-1): 3209, 3058, 1978, 1671, 1491, 1314. HRMS 
(ESI) m/z: [M+H]+ Calcd for C22H16BrN2O 403.0446;  found 
403.0441.. 1H NMR (400 MHz, DMSO-d6): δ 11.30 (s, 1H), 
9.73 (s, 1H), 7.74 (d, J = 7.4 Hz, 1H), 7.64 – 7.57 (m, 2H), 7.53 
(dq, J = 4.7, 4.1 Hz, 1H), 7.45 (d, J = 7.2 Hz, 2H), 7.40 – 7.25 
(m, 4H), 7.16 (dd, J = 8.6, 1.6 Hz, 1H), 6.94 (dd, J = 15.7, 1.8 
Hz, 2H). 13C {1H} (101 MHz, DMSO-d6): δ 168.6, 150.6, 142.5, 
135.8, 132.1, 130.9, 128.5, 127.6, 126.9, 126.3, 125.9, 124.2, 
123.9, 123.3, 122.1, 116.5, 113.8, 111.4, 65.9. 
Reaction also performed on a 2.2 mmol from 3-hydroxy-3-
phenylisoindolin-1-one (500 mg, 2.20 mmol), Ca(NTf2)2 (13 
mg, 0.02 mmol) and nBu4NPF6 (9 mg, 0.02 mmol) with 5-
bromoindole (653 mg, 3.33 mmol) in DCE (10 mL) for 2.5 h. 
Purification (3:1 EtOAc:Hex) afforded the product as a cream 
solid (880 mg, 98%)
3-[3,5-bis(trifluoromethyl)phenyl]-3-(5-bromo-1H-indol-3-yl)-
2,3-dihydro-1H-isoindol-1-one (3b). To a 4 mL vial was added 
3-hydroxy-3-(3,5-bis(trifluoromethyl))isoindolin-1-one (50
mg, 0.14 mmol), Ca(NTf2)2 (4 mg, 0.0069 mmol) and
nBu4NPF6 (3 mg, 0.0069 mmol) in DCE (1 mL) at 80 ºC. The 
reaction was stirred for 1 minute and 5-bromoindole (41 mg, 
0.21 mmol) was added in a single portion and stirred at 80 ºC 
for 30 minutes. Once TLC analysis indicated conversion to the 
product, the product was concentrated and purified by flash 
column chromatography (1:1, EtOAC:Hex) to afford a cream 
solid (68 mg, 91%). RF (1:1 EtOAc/Hex) = 0.33 . IR νmax (cm-
1): 3333, 3185, 3052, 1978, 1669, 1368. HRMS (ESI) m/z: 
[M+H]+ Calcd for C24H14BrF6N2O 539.0194;  found 539.0188. 
1H NMR (400 MHz, DMSO-d6): δ 11.44 (s, 1H), 9.91 (s, 1H), 
8.16 (s,1H), 8.11 (s, 2H), 7.79 (dd, J = 15.3, 7.5 Hz, 2H), 7.67 
(t, J = 7.4 Hz, 1H), 7.60 (t, J = 7.4 Hz, 1H), 7.38 (d, J = 8.6 Hz, 
1H), 7.19 (dd, J = 8.7, 1.3 Hz, 1H), 6.98 (d, J = 2.4 Hz, 1H), 
6.83 (s, 1H). 13C{1H} NMR (101 MHz, DMSO-d6):δ 168.4, 
149.0, 145.9, 135.8, 132.8, 130.8, 130.5(q, JF = 32.3 Hz), 
129.3, 127.0, 126.9, 126.3, 124.6, 124.3, 124.2, 123.6, 
122.1, 121.8, 121.4, 115.1, 114.1, 111.7, 65.5.
3-(5-bromo-1H-indol-3-yl)-3-(4-methoxyphenyl)-2,3-dihydro-
1H-isoindol-1-one (3c). To a 4 mL vial was added 3-(4-
methoxyphenyl)-3-hydroxyisoindolin-1-one (50 mg, 0.20 
mmol mmol), Ca(NTf2)2 (1.1 mg, 0.002 mmol) and nBu4NPF6 
(0.8 mg, 0.002 mmol) in DCE (1 mL) at 80 ºC. The reaction 
was stirred for 1 minute and 5-bromoindole (58 mg, 0.29 mmol) 





























































was added in a single portion and stirred at 80 ºC for 30 minutes. 
Once TLC analysis indicated conversion to the product, the 
product was concentrated and purified by flash column 
chromatography (1:1, EtOAc:Hex) to afford a cream solid (79 
mg, 93%). RF (1:1 EtOAc/DCM) = 0.41. IR νmax (cm-1): 3169, 
3040, 2838, 1668, 1608, 1255. HRMS (ESI) m/z: [M+H]+  
Calcd for C23H18BrN2O2 433.0552; ; found 433.0549.. 1H NMR 
(400 MHz, DMSO-d6): δ 11.28 (s, 1H), 9.67 (s, 1H), 7.73 (d, J 
= 7.3 Hz, 1H), 7.65 – 7.46 (m, 3H), 7.34 (t, J = 8.6 Hz, 3H), 
7.16 (d, J = 8.5 Hz, 1H), 7.01 (s, 1H), 6.99 – 6.79 (m, 3H), 3.72 
(s, 3H). 13C{1H}NMR (101 MHz, DMSO-d6): δ 168.5, 158.6, 
150.9, 135.8, 134.4, 132.0, 130.9, 128.4, 127.6, 126.9, 125.9, 
124.1, 123.9, 123.2, 122.2, 116.7, 113.8, 113.7, 111.4, 65.50, 
55.11.
3-(5-bromo-1H-indol-3-yl)-3-(thiophen-2-yl)-2,3-dihydro-1H-
isoindol-1-one (3d). To a 4 mL vial was added 3-hydroxy-3-
(thiophen-2-yl)isoindolin-1-one (50 mg, 0.22 mmol), 
Ca(NTf2)2 (1.3 mg, 0.0022 mmol) and nBu4NPF6 (0.9 mg, 
0.0022 mmol) in DCE (1 mL) at 80 ºC. The reaction was stirred 
for 1 minute and 5-bromoindole (64 mg, 0.32 mmol) was added 
in a single portion and stirred at 80 ºC for 30 minutes. Once 
TLC analysis indicated conversion to the product, the product 
was concentrated and purified by flash column chromatography 
(1:1 EtOAc:DCM) to afford a light brown solid (85 mg, 96%). 
RF (1:1 EtOAc/DCM) = 0.38. IR νmax (cm-1): 3172, 3041, 2851, 
1667, 1466, 1356. HRMS (ESI) m/z: [M+H]+ Calcd for 
C20H14BrN2OS 409.0010 ; found 409.0007. Cald. 1H NMR (400 
MHz, DMSO-d6): δ 11.36 (m, 1H), 9.85 (s, 1H), 7.76 (d, J = 7.4 
Hz, 1H), 7.68 – 7.51 (m, 3H), 7.45 (d, J = 5.0 Hz, 1H), 7.35 (d, 
J = 8.6 Hz, 1H), 7.17 (dd, J = 8.6, 1.6 Hz, 1H), 7.08 (m, 2H), 
7.05 – 6.92 (m, 2H). 13C{1H} NMR (101 MHz, DMSO-d6): δ 
168.3, 150.6, 147.3, 135.7, 132.3, 130.5, 128.8, 127.2, 126.7, 
126.0, 125.7, 125.5, 124.0, 123.9, 123.2, 121.9, 115.4, 113.9, 
111.6, 63.53.
3-(2H-1,3-benzodioxol-5-yl)-3-(5-bromo-3a,7a-dihydro-1H-
indol-2-yl)-2,3-dihydro-1H-isoindol-1-one (3e). To a 4 mL vial 
was added 3-(benzo[d][1,3]dioxol-5-yl)isoindolin-1-one (50 
mg, 0.19 mmol), Ca(NTf2)2 (1.1 mg, 0.0019 mmol) and 
nBu4NPF6 (0.7 mg, 0.0019 mmol) in DCE (1 mL) at 80 ºC. The 
reaction was stirred for 1 minute and 5-bromoindole (64 mg, 
0.32 mmol) was added in a single portion and stirred at 80 ºC 
for 30 minutes. Once TLC analysis indicated conversion to the 
product, the product was concentrated and purified by flash 
column chromatography (2:1, EtOAc:Hex) to afford a cream 
solid (78 mg, 94%). RF (2:1 EtOAc/Hex) = 0.17. IR νmax (cm-
1): 3219, 2896, 1674, 1611, 1485, 1237. HRMS (ESI) m/z: 
[M+H]+ Calcd for C23H16BrN2O3 447.0344 ; found 447.0350. 
1H NMR (400 MHz, CDCl3): δ 8.25 (s, 1H), 7.89 (d, J = 7.4 Hz, 
1H), 7.63 – 7.40 (m, 3H), 7.31 – 7.21 (m, 2H), 7.16 (s, 1H), 6.96 
– 6.85 (m, 3H), 6.82 (d, J = 1.8 Hz, 1H), 6.72 (d, J = 8.2 Hz,
1H), 5.95 (dd, J = 6.6, 1.1 Hz, 2H). 13C{1H} NMR (101 MHz,
CDCl3): δ 169.9, 150.9, 148.3, 147.7, 135.9, 135.3, 132.6,
128.8, 127.3, 125.9, 124.6, 124.3, 123.7, 122.7, 119.9, 117.7,
113.7, 113.3, 108.5, 107.2, 101.5, 66.5.
3-phenyl-3-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
3a,7a-dihydro-1H-indol-2-yl]-2,3-dihydro-1H-isoindol-1-one
(3f). To a 4 mL vial was added 3-hydroxy-3-phenylisoindolin-
1-one (50 mg, 0.22 mmol), Ca(NTf2)2 (1.3 mg, 0.0022 mmol) 
and nBu4NPF6 (0.9 mg, 0.0022 mmol) in DCE (1 mL) at 80 ºC. 
The reaction was stirred for 1 minute and 5-(4,4,5,5-
Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole (81 mg, 0.33 
mmol) was added in a single portion and stirred at 80 ºC for 1h. 
Once TLC analysis indicated conversion to the product, the 
product was concentrated and purified by flash column 
chromatography (2:1, EtOAc:Hex) to afford a white solid (90 
mg, 90%). RF (3:1 EtOAc/Hex) = 0.48. IR νmax (cm-1): 3257, 
2976, 1683, 1613, 1352, 1142. HRMS (ESI) m/z: [M+H]+ 
Calcd for C28H28BN2O3 451.2193; found 451.2204. 1H NMR 
(400 MHz, DMSO-d6): δ 11.20 (s, 1H), 9.73 (s, 1H), 7.74 (d, J 
= 7.3 Hz, 1H), 7.65 – 7.44 (m, 4H), 7.44 – 7.22 (m, 7H), 6.88 
(d, J = 2.2 Hz, 1H), 1.22 (s, 12H). 13C{1H} NMR (101 MHz, 
DMSO-d6): δ 168.6, 151.1, 142.9, 139.2, 131.9, 131.0, 128.4, 
128.3, 127.7, 127.5, 127.5, 126.5, 124.8, 124.3, 124.2, 123.2, 
117.2, 111.2, 83.0, 66.2, 24.8, 24.6.
3-(4-chlorophenyl)-3-[5-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-3a,7a-dihydro-1H-indol-2-yl]-2,3-dihydro-
1H-isoindol-1-one (3g). To a 4 mL vial was added 3-(4-
chlorophenyl)-3-hydroxyisoindolin-1-one (50 mg, 0.19 mmol), 
Ca(NTf2)2 (1mg, 0.0019 mmol) and nBu4NPF6 (0.8 mg, 0.0019 
mmol) in DCE (1 mL) at 80 ºC. The reaction was stirred for 1 
minute and 5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-
1H-indole (70 mg, 0.29 mmol) was added in a single portion 
and stirred at 80 ºC for 30 mins. Once TLC analysis indicated 
conversion to the product, the product was concentrated and 
purified by flash column chromatography (1:1, EtOAc:Hex) to 
afford a white solid (87 mg, 93%). RF (1:1 EtOAc/Hex) = 0.19. 
IR νmax (cm-1): 3237, 2977, 1673, 1613, 1469, 1352. HRMS 
(ESI) m/z: [M+H]+ Calcd for C28H27BClN2O3 485.1803; found 
485.1815. . 1H NMR (400 MHz, DMSO-d6): δ 11.24 (d, J = 1.9 
Hz, 1H), 9.77 (s, 1H), 7.74 (d, J = 7.3 Hz, 1H), 7.64 – 7.49 (m, 
3H), 7.46 – 7.29 (m, 7H), 6.89 (d, J = 2.1 Hz, 1H), 1.23 (s, 12H). 
13C{1H}NMR (101 MHz, DMSO-d6): δ 168.6, 150.7, 142.0, 
139.2, 132.2, 132.2, 131.0, 128.5, 128.4, 127.6, 127.6, 124.9, 
124.7, 124.1, 123.3, 116.7, 111.3, 83.03, 65.8, 24.8, 24.7.
3-(2-methoxyphenyl)-3-[5-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-3a,7a-dihydro-1H-indol-2-yl]-2,3-dihydro-
1H-isoindol-1-one (3h). To a 4 mL vial was added 3-hydroxy-
3-(2-methoxyphenyl)isoindolin-1-one (50 mg, 0.20 mmol), 
Ca(NTf2)2 (1.2 mg, 0.0020 mmol) and nBu4NPF6 (0.8 mg, 
0.0020 mmol) in DCE (1 mL) at 80 ºC. The reaction was stirred 
for 1 minute and 5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-
yl)-1H-indole (71 mg, 0.29 mmol) was added in a single portion 
and stirred at 80 ºC for 30 mins. Once TLC analysis indicated 
conversion to the product, the product was concentrated and 
purified by flash column chromatography (2:1, EtOAc:Hex) to 
afford an off white solid (92 mg, 98%). RF (2:1 EtOAc/Hex) = 
0.17. IR νmax (cm-1): 3414, 3264, 3008, 1680, 1612, 1351. 
HRMS (ESI) m/z: [M+H]+ Calcd for C29H30BN2O4 481.2299; 
found 481.2314. 1H NMR (400 MHz, DMSO-d6): δ 11.06 (d, J 
= 1.9 Hz, 1H), 9.16 (s, 1H), 7.79 – 7.69 (m, 1H), 7.58 – 7.46 
(m, 4H), 7.40 – 7.28 (m, 3H), 7.21 (dd, J = 7.7, 1.5 Hz, 1H), 
7.04 (d, J = 7.7 Hz, 1H), 6.93 – 6.85 (m, 1H), 6.82 (d, J = 2.4 
Hz, 1H), 3.51 (s, 3H), 1.23 (s, 12H). 13C{1H} NMR (101 MHz, 
DMSO-d6): δ 168.6, 157.9, 150.7, 139.0, 131.6, 131.4, 129.7, 
129.5, 128.1, 127.7, 127.4, 127.2, 124.7, 124.6, 123.5, 123.1, 
119.9, 117.1, 112.6, 111.1, 83.0, 79.2, 65.4, 55.4, 24.1, 24.7.
3-(furan-2-yl)-3-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)-3a,7a-dihydro-1H-indol-2-yl]-2,3-dihydro-1H-isoindol-1-
one (3i). To a 4 mL vial was added 3-hydroxy-3-(furan-2-
yl)isoindolin-1-one (50 mg, 0.23 mmol), Ca(NTf2)2 (1.4 mg, 
0.0023 mmol) and nBu4NPF6 (0.9 mg, 0.0023 mmol) in DCE 
(1 mL) at 80 ºC. The reaction was stirred for 1 minute and 5-






























































(85 mg, 0.35 mmol) was added in a single portion and stirred at 
80 ºC for 30 mins. Once TLC analysis indicated conversion to 
the product, the product was concentrated and purified by flash 
column chromatography (1:1 EtOAc:Hex) to afford a pale 
orange solid (84 mg, 82%). RF (2:1 EtOAc/Hex) = 0.35. IR νmax 
(cm-1): 3295, 3059, 2869, 1679, 1614, 1377. HRMS (ESI) m/z: 
[M+H]+ Calcd for C26H26BN2O4 441.1989; found 441.1993.. 1H 
NMR (400 MHz, DMSO-d6): δ 11.25 (d, J = 2.1 Hz, 1H), 9.70 
(s, 1H), 7.80 – 7.73 (m, 1H), 7.70 – 7.65 (m, 1H), 7.63 – 7.50 
(m, 3H), 7.41 – 7.30 (m, 3H), 6.97 (d, J = 2.5 Hz, 1H), 6.45 (dd, 
J = 3.2, 1.8 Hz, 1H), 6.30 (dd, J = 3.2, 0.6 Hz, 1H), 1.25 (s, 
12H). 13C{1H} NMR (101 MHz, DMSO-d6): δ 169.0, 155.3, 
149.5, 143.7, 139.4, 132.6, 131.6, 129.2, 127.9, 127.5, 125.0, 
124.4, 123.6, 115.5, 111.8, 110.9, 107.5, 83.5, 62.6, 25.3, 25.2.
3-[3,5-bis(trifluoromethyl)phenyl]-3-[5-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)-3a,7a-dihydro-1H-indol-2-yl]-2,3-
dihydro-1H-isoindol-1-one (3j). To a 4 mL vial was added 3-
hydroxy-3-(3,5-bis(trifluoromethyl))isoindolin-1-one (50 mg, 
0.14 mmol), Ca(NTf2)2 (0.8 mg, 0.0014 mmol) and nBu4NPF6 
(0.5 mg, 0.0014 mmol) in DCE (1 mL) at 80 ºC. The reaction 
was stirred for 1 minute and 5-(4,4,5,5-Tetramethyl-1,3,2-
dioxaborolan-2-yl)-1H-indole (51 mg, 0.21 mmol) was added 
in a single portion and stirred at 80 ºC for 30 mins. Once TLC 
analysis indicated conversion to the product, the product was 
concentrated and purified by flash column chromatography 
(1:1, EtOAc:Hex) to afford an off white solid (66 mg, 81%). RF 
(1:1 EtOAc/Hex) = 0.30. IR νmax (cm-1): 3273, 2980, 1695, 
1355, 1275, 1131. HRMS (ESI) m/z: [M+H]+ Calcd for 
C30H26BF6N2O3 587.1941; found 587.1947.. 1H NMR (400 
MHz, CDCl3): δ 8.56 (s, 1H), 7.99 – 7.88 (m, 3H), 7.81 (s, 1H), 
7.69 – 7.57 (m, 2H), 7.57 – 7.48 (m, 1H), 7.43 (d, J = 7.6 Hz, 
1H), 7.41 – 7.29 (m, 2H), 7.18 (s, 1H), 1.28 (s, 12H). 13C{1H} 
NMR (101 MHz, CDCl3): δ 170.2, 149.6, 145.3, 139.4, 133.2 
(q, JF = 33.4 Hz), 132.0, 130.1, 129.3, 129.3, 126.8, 126.8, 
125.0, 124.7, 124.6, 123.8, 123.6, 122.2, 121.9, 116.3, 111.6, 
83.75, 66.24, 24.9, 24.8.
3-phenyl-3-phenylsulfanyl-2,3-dihydro-isoindol-1-one (4a). To
a 4 mL vial was added 3-hydroxy-3-phenylisoindolin-1-one (50
mg, 0.22 mmol), Ca(NTf2)2 (3 mg, 0.0022 mmol) and
nBu4NPF6 (1.7 mg, 0.0022 mmol) in DCE (1 mL) at 80 ºC. The 
reaction was stirred for 5 minutes and thiophenol (29 mg, 0.27 
mmol) was added in a single portion and stirred at 80 ºC for 15 
minutes. Once TLC analysis indicated conversion to the 
product, the product was concentrated and purified by flash 
column chromatography (1:1, EtOAc:Hex) to afford a white 
solid (54 mg, 77%). RF (1:1 EtOAc/Hex) = 0.43. IR νmax (cm-
1): 3062, 2848, 1696, 1494, 1345, 742. HRMS (ESI) m/z: 
[M+H]+ Calcd for C20H16NOS 318.0953; found 318.0947. 1H 
NMR (400 MHz, CDCl3): δ 7.84 – 7.75 (m, 2H), 7.73 – 7.67 
(m, 1H), 7.56 (td, J = 7.5, 1.1 Hz, 1H), 7.51 – 7.29 (m, 6H), 7.24 
– 7.18 (m, 1H), 7.14 (dt, J = 8.2, 1.7 Hz, 1H), 7.08 – 7.02 (m,
2H). 13C{1H} NMR (101 MHz, CDCl3): δ 169.2, 148.7, 139.1, 
137.1, 132.6, 129.9, 129.8, 129.4, 129.2, 129.0, 128.7, 128.6, 
126.1, 123.9, 123.4, 75.79.
Reaction also performed on a 2.0 mmol from 3-hydroxy-3-
phenylisoindolin-1-one (450 mg, 2.0 mmol), Ca(NTf2)2 (12 mg, 
0.02 mmol) and nBu4NPF6 (8 mg, 0.02 mmol) with thiophenol 
(265 mg, 2.40 mmol) in DCE (9 mL) for 30 min. Purification 
(1:1 EtOAc:Hex) afforded the product as a white solid (608 mg, 
96%)
3-(4-methoxyphenyl)-3-(phenylthio)isoindolin-1-one (4b). To a 
4 mL vial was added 3-(4-methoxyphenyl)-3-
hydroxyisoindolin-1-one (60 mg, 0.24 mmol), Ca(NTf2)2 (1.5 
mg, 0.0024 mmol) and nBu4NPF6 (1 mg, 0.0024 mmol) in DCE 
(1 mL) at 80 ºC. The reaction was stirred for 5 minutes and 
thiophenol (39 mg, 0.353 mmol) was added in a single portion 
and stirred at 80 ºC for 15 minutes. Once TLC analysis indicated 
conversion to the product, the product was concentrated and 
purified by flash column chromatography (1:1 EtOAc:Hex) to 
afford a white solid (70 mg, 86%). RF (1:1 EtOAc/CycHex) = 
0.53. IR νmax (cm-1): 3057, 2930, 2849, 1700, 1606, 1509. 
HRMS (ESI) m/z: [M+H]+ Calcd for C21H18NO2S 348.1058; 
found 348.1053. 1H NMR (400 MHz, CDCl3): δ 7.74 – 7.64 (m, 
3H), 7.61 – 7.51 (m, 1H), 7.46 (d, J = 7.5 Hz, 1H), 7.35 – 7.28 
(m, 1H), 7.24 – 7.18 (m, 1H), 7.17 – 7.11 (m, 3H), 7.11 – 7.01 
(m, 2H), 6.97 – 6.88 (m, 2H), 3.81 (s, 3H). 13C{1H} NMR (101 
MHz, CDCl3): 169.1, 160.0, 148.9, 137.1, 132.5, 131.1, 131.04, 
129.9, 129.8, 129.6, 128.6, 127.5, 123.8, 123.4, 114.4, 75.5, 
55.5..
3-(4-chlorophenyl)-3-(phenylthio)isoindolin-1-one (4c). To a 4 
mL vial was added 3-(4-chlorophenyl)-3-hydroxyisoindolin-1-
one (100 mg, 0.39 mmol), Ca(NTf2)2 (2 mg, 0.0039 mmol) and 
nBu4NPF6 (1.5 mg, 0.0039 mmol) in DCE (2 mL) at 80 ºC. The 
reaction was stirred for 5 minutes and thiophenol (64 mg, 0.578 
mmol) was added in a single portion and stirred at 80 ºC for 15 
minutes. Once TLC analysis indicated conversion to the 
product, the product was concentrated and purified by flash 
column chromatography (1:1, EtOAC:Hex) to afford a white 
solid (116 mg, 86%). RF (1:1 EtOAc/CycHex) = 0.6. IR νmax 
(cm-1): 3130, 3062, 2851, 1702, 1470, 1096. HRMS (ESI) m/z: 
[M+H]+ Calcd for C20H15ClNOS 352.0563; found 352.0559. 1H 
NMR (400 MHz, DMSO-d6): 9.84 (s, 1H), 7.98 – 7.72 (m, 3H), 
7.72 – 7.59 (m, 1H),7.58-7.56 (m, 2H), 7.45 – 7.20 (m, 3H), 
7.20 – 6.90 (m, 4H). 13C{1H} NMR (101 MHz, DMSO-d6): 
δ167.7, 147.5, 138.5, 136.71, 133.4, 132.4, 130.3, 129.7, 129.1, 
128.9, 128.8, 128.4, 128.0, 124.0, 122.4, 74.9.
4-(1-Hydroxy-3-oxoisoindolin-1-yl)benzonitrile (4d). To a 4 
mL vial was added 4-(1-hydroxy-3-oxoisoindolin-1-
yl)benzonitrile (50 mg, 0.20 mmol), Ca(NTf2)2 (1.2 mg, 0.002 
mmol) and nBu4NPF6 (0.8 mg, 0.002 mmol) in DCE (1 mL) at 
80 ºC. The reaction was stirred for 5 minutes and thiophenol (33 
mg, 0.3 mmol) was added in a single portion and stirred at 80 
ºC for 15 minutes. Once TLC analysis indicated conversion to 
the product, the product was concentrated and purified by flash 
column chromatography (1:1, EtOAc:Hex) to afford a cream 
solid (54 mg, 79%). RF (1:1 EtOAc/CycHex) = 0.50. IR νmax 
(cm-1): 3215, 3075, 2229, 1714, 1679, 1497. HRMS (ESI) m/z: 
[M+H]+ Calcd for C21H15N2OS 343.0905;  found 343.0907. 1H 
NMR (400 MHz, CDCl3): δ 7.93 (d, J = 8.5 Hz, 2H), 7.71 (d, J 
= 8.5 Hz, 2H), 7.68 – 7.57 (m, 2H), 7.54 – 7.46 (m, 2H), 7.38 
(t, J = 7.3 Hz, 1H), 7.25 – 7.21 (m, 1H), 7.14 (d, J = 6.9 Hz, 
2H), 7.11 – 7.04 (m, 2H). 13C{1H} NMR (101 MHz, CDCl3): δ 
169.3, 147.7, 144.5, 137.1, 133.0, 132.9, 130.2, 129.3, 128.9, 
128.7, 127.2, 123.8, 123.7, 118.4, 112.9, 75.1.
3-(4-trifluoromethylphenyl)-3-(phenylthio)isoindolin-1-one 
(4e). To a 4 mL vial was added 3-hydroxy-3-(4-
(trifluoromethyl)phenyl)isoindolin-1-one (60 mg, 0.21 mmol), 
Ca(NTf2)2 (1.2 mg, 0.0021 mmol) and nBu4NPF6 (0.8 mg, 





























































0.0021 mmol) in DCE (1 mL) at 80 ºC. The reaction was stirred 
for 5 minutes and thiophenol (34 mg, 0.307 mmol) was added 
in a single portion and stirred at 80 ºC for 15 minutes. Once 
TLC analysis indicated conversion to the product, the product 
was concentrated and purified by flash column chromatography 
(1:1, EtOAc:Hex) to afford a white solid (76 mg, 96%). RF (1:1 
EtOAc/CycHex) = 0.60. IR νmax (cm-1): 3126, 3071, 1699, 1496, 
1392. HRMS (ESI) m/z: [M+H]+ Calcd for C21H15F3NOS 
386.0826; found 386.0823.. 1H NMR (400 MHz, CDCl3): δ 7.93 
(d, J = 8.3 Hz, 1H), 7.73 – 7.62 (m, 2H), 7.59 (t, J = 7.0 Hz, 
1H), 7.50 (d, J = 7.5 Hz, 1H), 7.36 (t, J = 7.3 Hz, 1H), 7.24 - 
7.23 (m, 3.6 Hz, 1H), 7.15 – 7.07 (m, 3H). 13C{1H} NMR (101 
MHz, CDCl3): δ 169.1, 148.1, 143.3, 137.1, 132.9, 130.1, 129.7, 
129.2, 128.9, 128.8, 126.7, 126.2, 126.2, 123.7, 75.2.
3-(2-methoxyphenyl)-3-(phenylthio)isoindolin-1-one (4f). To a 
4 mL vial was added 3-(2-methoxyphenyl)-3-
hydroxyisoindolin-1-one (100 mg, 0.39 mmol), Ca(NTf2)2 (2.4 
mg, 0.0039 mmol) and nBu4NPF6 (1.5 mg, 0.0039 mmol) in 
DCE (2 mL) at 80 ºC. The reaction was stirred for 5 minutes 
and thiophenol (65 mg, 0.353 mmol) was added in a single 
portion and stirred at 80 ºC for 15 minutes. Once TLC analysis 
indicated conversion to the product, the product was 
concentrated and purified by flash column chromatography 
(1:1, EtOAc:Hex) to afford a white solid (115 mg, 84%). RF 
(1:1 EtOAc/CycHex) = 0.40. IR νmax (cm-1): 3283, 3051, 2932, 
1692, 1489, 1249. HRMS (ESI) m/z: [M+H]+ Calcd for 
C21H18NO2S 348.1058; found 348.1050. 1H NMR (400 MHz, 
CDCl3): δ 7.95 – 7.80 (m, 2H), 7.64 (td, J = 7.6, 1.1 Hz, 1H), 
7.59 – 7.47 (m, 2H), 7.44 – 7.32 (m, 2H), 7.21 – 7.14 (m, 1H), 
7.14 – 7.09 (m, 2H), 7.08 – 7.01 (m, 3H), 6.92 (td, J = 7.7, 1.1 
Hz, 1H), 4.02 (s, 3H). 13C{1H} NMR (101 MHz, CDCl3): δ 
168.0, 157.8, 146.4, 136.8, 131.5, 131.4, 130.5, 129.4, 128.7, 
128.4, 127.4, 126.5, 125.6, 123.5, 120.8, 112.8, 74.5, 56.2.
3-(3,5-bis(trifluoromethyl))-3-(phenylthio)isoindolin-1-one 
(4g). To a 4 mL vial was added 3-hydroxy-3-(3,5-
bis(trifluoromethyl))isoindolin-1-one (100 mg, 0.28 mmol), 
Ca(NTf2)2 (1.7 mg, 0.0028 mmol) and nBu4NPF6 (1 mg, 0.0028 
mmol) in DCE (2 mL) at 80 ºC. The reaction was stirred for 5 
minutes and thiophenol (46 mg, 0.42 mmol) was added in a 
single portion and stirred at 80 ºC for 15 minutes. Once TLC 
analysis indicated conversion to the product, the product was 
concentrated and purified by flash column chromatography 
(2:3, EtOAc:Hex) to afford a white solid (113 mg, 90%). RF 
(2:3 EtOAc/CycHex) = 0.56. IR νmax (cm-1): 3208, 3094, 1715, 
1469, 1312, 1280. HRMS (ESI) m/z: [M+H]+ Calcd for 
C22H14F6NOS 454.0700; found 454.0699. 1H NMR (400 MHz, 
CDCl3): δ 8.26 (s, 2H), 7.89 (s, 1H), 7.64 – 7.62 (m, 2H), 7.53 
(d, J = 7.7 Hz, 1H), 7.47 – 7.36 (m, 1H), 7.28 – 7.24 (m, 2H), 
7.20 – 7.05 (m, 4H). 13C{1H} NMR (101 MHz, CDCl3): δ 167.6, 
146.1, 142.6, 136.7, , 131.6 (d, J = 238 Hz), 131.1, 130.8, , 
130.1, 129.4, 128.6, 128.6, 126.8, , 124.2, 123.1 (d, J = 275 Hz), 
123.0, 122.8, , 74.5.
3-(thiophen-2-yl)-3-(phenylthio)isoindolin-1-one (4h). To a 4 
mL vial was added 3-hydroxy-3-(thiophen-2-yl)isoindolin-1-
one (100 mg, 0.43 mM), Ca(NTf2)2 (2.4 mg, 0.0043 mmol) and
nBu4NPF6 (1.5 mg, 0.0043 mmol) in DCE (2 mL) at 80 ºC. The 
reaction was stirred for 5 minutes and thiophenol (72 mg, 0.65 
mmol) was added in a single portion and stirred at 80 ºC for 15 
minutes. Once TLC analysis indicated conversion to the 
product, the product was concentrated and purified by flash 
column chromatography (1:1, EtOAc:Hex) to afford a light 
brown solid (120 mg, 86%). RF (1:1 EtOAc/CycHex) = 0.60. 
IR νmax (cm-1): 3155, 3060, 2836, 1691, 1470, 1354. HRMS 
(ESI) m/z: [M+H]+ Calcd for C18H14NOS2 324.0517;  found 
324.0516. 1H NMR (400 MHz, CDCl3): δ 7.75 (d, J = 7.8 Hz, 
1H), 7.59 (td, J = 7.5, 0.9 Hz, 1H), 7.50 (d, J = 7.5 Hz, 1H), 
7.39 – 7.29 (m, 3H), 7.24 – 7.23 (m, 1H), 7.18 – 7.16 (m, 2H), 
7.13 – 7.05 (m, 2H), 7.01 (dd, J = 5.0, 3.7 Hz, 1H), 6.92 – 6.91 
(m, 1H). 13C{1H} NMR (101 MHz, CDCl3): δ 168.8, 148.2, 
143.0, 136.9, 132.7, 130.0, 129.5, 129.5, 129.1, 128.7, 127.6, 
126.4, 125.7, 123.8, 123.4, 72.8.
3-(furan-2-yl)-3-(phenylthio)isoindolin-1-one (4i). To a 4 mL 
vial was added 3-hydroxy-3-(furan-2-yl)isoindolin-1-one (50
mg, 0.23 mmol), Ca(NTf2)2 (1.4 mg, 0.0023 mmol) and 
nBu4NPF6 (1 mg, 0.0023 mmol) in DCE (1 mL) at 80 ºC. The 
reaction was stirred for 5 minutes and thiophenol (38 mg, 0.35 
mmol) was added in a single portion and stirred at 80 ºC for 15 
minutes. Once TLC analysis indicated conversion to the 
product, the product was concentrated and purified by flash 
column chromatography (1:1, EtOAc:Hex) to afford a light 
brown solid (70 mg, 98%). RF (1:1 EtOAc/CycHex) = 0.6. IR 
νmax (cm-1): 3153, 3060, 1689, 1500, 1307, 1154. HRMS (ESI) 
m/z: [M+H]+ Calcd for C18H14NO2S 308.0745; found 308.0748. 
1H NMR (400 MHz, CDCl3): δ 7.86 (t, J = 10.3 Hz, 1H), 7.65 
– 7.57 (m, 2H), 7.51 (d, J = 0.9 Hz, 1H), 7.42 (t, J = 7.6 Hz,
1H), 7.31 – 7.20 (m, 2H), 7.18 – 7.10 (m, 4H), 6.94 (s, 1H), 6.37
– 6.28 (m, 2H). 13C{1H} NMR (101 MHz, DMSOd-6): δ 167.6,
150.7, 145.8, 144.0, 136.7, 132.4, 130.4, 129.7, 129.2, 128.6,
128.5, 124.1, 122.4, 110.9, 108.2, 70.6.
3-(benzo[d][1,3]dioxol-5-yl)-3-(phenylthio)isoindolin-1-one 
(4j). To a 4 mL vial was added 3-(benzo[d][1,3]dioxol-5-
yl)isoindolin-1-one (80 mg, 0.30 mmol), Ca(NTf2)2 (1.8 mg, 
0.003 mmol) and nBu4NPF6 (1.2 mg, 0.003 mmol) in DCE (1 
mL) at 80 ºC. The reaction was stirred for 5 minutes and 
thiophenol (33 mg, 0.3 mmol) was added in a single portion and 
stirred at 80 ºC for 15 minutes. Once TLC analysis indicated 
conversion to the product, the product was concentrated and 
purified by flash column chromatography (1:1, EtOAc:Hex) to 
afford a peach solid (98 mg, 91%). RF (1:1 EtOAc/CycHex) = 
0.56. IR νmax (cm-1): 3209, 2902, 1706, 1671, 1485, 1246. 
HRMS (ESI) m/z: [M+H]+ Calcd for C21H16NO3S 362.0851;  
found 362.0852. 1H NMR (400 MHz, CDCl3): δ 9.74 (s, 1H), 
7.88 (d, J = 7.7 Hz, 1H), 7.62 (t, J = 7.4 Hz, 1H), 7.38 – 7.30 
(m, 2H), 7.29 – 7.18 (m, 4H), 7.10 (d, J = 4.3 Hz, 5H), 6.96 (d, 
J = 8.2 Hz, 1H), 6.06 (s, 2H). 13C{1H} NMR (101 MHz, 
CDCl3):δ 167.6, 147.7, 147.4, 136.6, 133.2, 132.1, 130.4, 129.7, 
129.5, 128.6, 128.3, 124.2, 122.3, 119.3, 108.2, 106.8, 101.6, 
75.30.
3-((4-methoxyphenyl)thio)-3-phenylisoindolin-1-one (6a). To a 
4 mL vial was added 3-hydroxy-3-phenylisoindolin-1-one (100 
mg, 0.44 mmol), Ca(NTf2)2 (3 mg, 0.0044 mmol) and 
nBu4NPF6 (1.7 mg, 0.0044 mmol) in DCE (2 mL) at 80 ºC. The 
reaction was stirred for 5 minutes and 4-methoxythiophenol (75 
mg, 0.533 mmol) was added in a single portion and stirred at 80 
ºC for 15 minutes. Once TLC analysis indicated conversion to 
the product, the product was concentrated and purified by flash 
column chromatography (1:1, EtOAc:Hex) to afford a cream 
solid (121 mg, 78%). RF (1:1 EtOAc/Hex) = 0.26. IR νmax (cm-





























































1): 3198, 3078, 2840, 1698, 1589, 1243. HRMS (ESI) m/z: 
[M+H]+ Calcd for C21H18NO2S 348.1058;  found 348.1059. 1H 
NMR (400 MHz, DMSO-d6): δ 9.73 (s, 1H), 7.86 (d, J = 7.8 Hz, 
1H), 7.78 (d, J = 7.6 Hz, 2H), 7.62 (t, J = 7.5 Hz, 1H), 7.46 (t, 
J = 7.5 Hz, 2H), 7.41 – 7.23 (m, 3H), 7.02 (d, J = 8.7 Hz, 2H), 
6.67 (d, J = 8.7 Hz, 2H), 3.66 (s, 3H). 13C{1H} NMR (101 MHz, 
DMSO-d6): δ 167.8, 160.4, 148.0, 139.5, 138.4, 132.1, 130.5, 
128.8, 128.6, 128.5, 126.0, 124.0, 122.3, 120.1, 113.9, 75.4, 
55.2.
3-((4-(trifluoromethyl)phenyl)thio)-3-phenylisoindolin-1-one 
(6b). To a 4 mL vial was added 3-hydroxy-3-phenylisoindolin-
1-one (100 mg, 0.44 mmol), Ca(NTf2)2 (2.7 mg, 0.0044 mmol) 
and nBu4NPF6 (1.7 mg, 0.0044 mmol) in DCE (2 mL) at 80 ºC. 
The reaction was stirred for 5 minutes and 4-
(trifluoromethyl)thiophenol (95 mg, 0.533 mmol) was added in 
a single portion and stirred at 80 ºC for 15 minutes. Once TLC 
analysis indicated conversion to the product, the product was 
concentrated and purified by flash column chromatography 
(1:1, EtOAc:Hex) to afford a cream solid (142 mg, 83%). RF 
(1:1 EtOAc/Hex) = 0.54. IR νmax (cm-1): 3160, 3062, 2850, 
1694, 1319, 1124. HRMS (ESI) m/z: [M+H]+ Calcd for 
C21H15F3NOS 386.0826; found 386.0828. 1H NMR (400 MHz, 
DMSO-d6): δ 9.96 (s, 1H), 7.90 (d, J = 7.8 Hz, 1H), 7.80 (d, J 
= 7.5 Hz, 2H), 7.65 (t, J = 7.2 Hz, 1H), 7.54 – 7.45 (m, 4H), 
7.45 – 7.35 (m, 2H), 7.35 – 7.27 (m, 3H). 13C{1H} NMR (101 
MHz, DMSO-d6): δ 167.7, 147.5, 139.1, 137.0, 134.9, 132.5, 
130.2, 129.8, 129.4, 129.0, 128.8, 126.0, 125.1, 125.1, 124.1, 
122.4, 75.8.
3-((4-chlorophenyl)thio)-3-phenylisoindolin-1-one (6c). To a 4 
mL vial was added 3-hydroxy-3-phenylisoindolin-1-one (100 
mg, 0.44 mmol), Ca(NTf2)2 (2.67 mg, 0.0044 mmol) and 
nBu4NPF6 (1.72 mg, 0.0044 mmol) in DCE (2 mL) at 80 ºC. 
The reaction was stirred for 5 minutes and 4-chlorothiophenol
(77 mg, 0.533 mmol) was added in a single portion and stirred 
at 80 ºC for 15 minutes. Once TLC analysis indicated 
conversion to the product, the product was concentrated and 
purified by flash column chromatography (1:1, EtOAc:Hex) to 
afford a cream solid (136 mg, 88%). RF (1:1 EtOAc/Hex) = 
0.50. IR νmax (cm-1): 3162, 3060, 2828, 1694, 1469, 1312. 
HRMS (ESI) m/z: [M+H]+ Calcd for C20H15ClNOS 352.0563; 
found 352.0562. 1H NMR (400 MHz, DMSO-d6): δ 9.86 (s, 
1H), 7.88 (d, J = 7.7 Hz, 1H), 7.78 (d, J = 7.6 Hz, 2H), 7.63 (dd, 
J = 10.8, 4.2 Hz, 1H), 7.52 – 7.42 (m, J = 7.3 Hz, 2H), 7.42 – 
7.29 (m, J = 15.2, 7.3Z Hz, 3H), 7.21 (d, J = 8.5 Hz, 2H), 7.11 
(d, J = 8.5 Hz, 2H). 13C{1H} NMR (101 MHz, DMSO-d6): δ 
167.8, 147.6, 139.2, 138.4, 134.9, 132.4, 130.3, 129.0, 128.9, 
128.7, 128.5, 126.0, 124.0, 122.4, 75.6.
3-((3,5-dimethylphenyl)thio)-3-phenylisoindolin-1-one (6d). 
To a 4 mL vial was added 3-hydroxy-3-phenylisoindolin-1-one 
(100 mg, 0.44 mmol), Ca(NTf2)2 (3 mg, 0.0044 mmol) and 
nBu4NPF6 (1.7 mg, 0.0044 mmol) in DCE (2 mL) at 80 ºC. The 
reaction was stirred for 5 minutes and 3,5-dimethylthiophenol 
(74 mg, 0.533 mmol) was added in a single portion and stirred 
at 80 ºC for 15 minutes. Once TLC analysis indicated 
conversion to the product, the product was concentrated and 
purified by flash column chromatography (1:1, EtOAc:Hex) to 
afford a cream solid (132 mg, 86%). RF (1:1 EtOAc/Hex) = 
0.75. IR νmax (cm-1): 3173, 3062, 2920, 2855, 1699, 1312. 
HRMS (ESI) m/z: [M+H]+ Calcd for C22H20NOS 346.1266; 
found 346.1263. 1H NMR (400 MHz, DMSO-d6): δ 9.74 (s, 
1H), 7.86 (d, J = 7.7 Hz, 1H), 7.78 (d, J = 7.7 Hz, 2H), 7.64 (t, 
J = 7.4 Hz, 1H), 7.45 (t, J = 7.5 Hz, 2H), 7.42 – 7.27 (m, 2H), 
6.87 (s, 1H), 6.68 (s, 2H), 2.04 (s, 6H). 13C{1H} NMR (101 
MHz, DMSO-d6): δ 167.8, 148.0, 139.5, 137.2, 134.2, 132.0, 
130.8, 130.6, 129.0, 128.9, 128.5, 126.0, 124.2, 122.2, 75.5, 
20.6.
3-((2-methoxyphenyl)thio)-3-phenylisoindolin-1-one (6e). To a 
4 mL vial was added 3-hydroxy-3-phenylisoindolin-1-one (100 
mg, 0.44 mmol), Ca(NTf2)2 (3 mg, 0.0044 mmol) and 
nBu4NPF6 (1.7 mg, 0.0044 mmol) in DCE (2 mL) at 80 ºC. The 
reaction was stirred for 5 minutes and 2-methoxythiophenol (93 
mg, 0.666 mmol) was added in a single portion and stirred at 80 
ºC for 15 minutes. Once TLC analysis indicated conversion to 
the product, the product was concentrated and purified by flash 
column chromatography (1:1, EtOAC:Hex) to afford a cream 
solid (151 mg, 98%). RF (1:1 EtOAc/Hex) = 0.25. IR νmax (cm-
1): 3190, 3065, 2925, 2830, 1695, 1471. HRMS (ESI) m/z: 
[M+H]+ Calcd for C21H18NO2S 348.1058; found 348.1060. 1H 
NMR (400 MHz, CDCl3): δ 7.79 (d, J = 7.5 Hz, 2H), 7.69 (d, J 
= 7.7 Hz, 1H), 7.52 (t, J = 7.5 Hz, 1H), 7.45 (d, J = 7.4 Hz, 1H), 
7.44 – 7.19 (m, 5H), 6.91 (d, J = 7.3 Hz, 1H), 6.81 – 6.73 (m, 
2H), 6.59 (t, J = 7.4 Hz, 1H), 3.80 (s, 3H). 13C{1H} NMR (101 
MHz, CDCl3): δ 160.9, 148.9, 139.5, 139.3, 132.3, 132.2, 129.0, 
128.8, 128.6, 126.0, 124.0, 123.0, 120.7, 117.2, 111.3, 76.3, 
55.9.
3-(2-pyrimidinethio)-3-phenylisoindolin-1-one (6f). To a 4 mL 
vial was added 3-hydroxy-3-phenylisoindolin-1-one (100 mg, 
0.44 mmol), Ca(NTf2)2 (3 mg, 0.0044 mmol) and nBu4NPF6 
(1.7 mg, 0.0044 mmol) in DCE (2 mL) at 80 ºC. The reaction 
was stirred for 5 minutes and 2-mercaptopyrimidine (75 mg, 
0.666 mmol) was added in a single portion and stirred at 80 ºC 
for 15 minutes. Once TLC analysis indicated conversion to the 
product, the product was concentrated and purified by flash 
column chromatography (3:1, EtOAC:Hex) to afford a white 
solid (111 mg, 78%). RF (3:1 EtOAc/Hex) = 0.6. IR νmax (cm-
1): 3288, 3057, 2924, 1693, 1609, 1377. HRMS (ESI) m/z: 
[M+Na]+ Calcd for C18H13N3OSNa 342.0672; found 342.0671. 
1H NMR (400 MHz, CDCl3): δ.81 (s, 1H), 8.42 (d, J = 4.9 Hz, 
2H), 7.90 (d, J = 7.1 Hz, 1H), 7.86 – 7.81 (m, 2H), 7.62 – 7.42 
(m, 3H), 7.32 – 7.26 (m, 2H), 7.26 – 7.19 (m, 1H), 6.96 (t, J = 
4.9 Hz, 1H). 13C{1H} NMR (101 MHz, CDCl3): δ 171.4, 169.4, 
157.5, 147.7, 140.2, 133.1, 130.2, 129.7, 128.8, 128.3, 126.2, 
124.6, 123.2, 117.7, 74.3.
3-(2-furfurylthio)-3-phenylisoindolin-1-one (6g). To a 4 mL 
vial was added 3-hydroxy-3-phenylisoindolin-1-one (100 mg, 
0.44 mmol), Ca(NTf2)2 (3 mg, 0.0044 mmol) and nBu4NPF6 
(1.7 mg, 0.0044 mmol) in DCE (2 mL) at 80 ºC. The reaction 
was stirred for 5 minutes and 2-furfurylthiol (76 mg, 0.666 
mmol) was added in a single portion and stirred at 80 ºC for 15 
minutes. Once TLC analysis indicated conversion to the 
product, the product was concentrated and purified by flash 
column chromatography (1:1, EtOAc:Hex) to afford a cream 
solid (143 mg, 78%). RF (1:1 EtOAc/Hex) = 0.39. IR νmax (cm-
1): 3170, 3061, 2926, 1692, 1467, 1148. HRMS (ESI) m/z: 
Calcd for C19H16NO2S 322.0902; found 322.0901. 1H NMR 
(400 MHz, DMSO-d6): δ  9.90 (s, 1H), 7.78 – 7.66 (m, J = 7.2 
Hz, 4H), 7.61 (t, J = 7.3 Hz, 1H), 7.56 – 7.48 (m, J = 7.3 Hz, 
1H), 7.46 (s, 1H), 7.43 – 7.36 (m, J = 7.1 Hz, 2H), 7.36 – 7.26 
(m, 1H), 6.25 (s, 1H), 5.92 (s, 1H), 3.50 (d, J = 14.0 Hz, 1H), 
3.42 (d, J = 14.0 Hz, 1H). 13C{1H} NMR (101 MHz, DMSO-
d6): δ 168.1, 149.7, 148.0, 142.5, 139.7, 132.8, 130.5, 129.2, 
128.9, 128.5, 125.9, 123.8, 123.0, 110.7, 107.8, 72.9, 26.4.





























































3-(benzylthio)-3-phenylisoindolin-1-one (6h). To a 4 mL vial 
was added 3-hydroxy-3-phenylisoindolin-1-one (100 mg, 0.44 
mmol), Ca(NTf2)2 (3 mg, 0.0044 mmol) and nBu4NPF6 (1.7 mg, 
0.0044 mmol) in DCE (2 mL) at 80 ºC. The reaction was stirred 
for 5 minutes and benzylmercaptan (66 mg, 0.53 mmol) was 
added in a single portion and stirred at 80 ºC for 15 minutes. 
Once TLC analysis indicated conversion to the product, the 
product was concentrated and purified by flash column 
chromatography (1:1, EtOAC:Hex) to afford a cream solid (135 
mg, 92%). RF (1:1 EtOAc/Hex) = 0.46. IR νmax (cm-1): 3127, 
3056, 2843, 1694, 1609, 1491. HRMS (ESI) m/z: [M+H]+ 
Calcd for C21H18NOS 332.1109; found 332.1104. 1H NMR (400 
MHz, DMSO-d6): δ 9.92 (s, 1H), 7.84 – 7.66 (m, 4H), 7.61 (t, J 
= 7.1 Hz, 1H), 7.51 (t, J = 7.3 Hz, 1H), 7.46 – 7.38 (m, 2H), 
7.38 – 7.27 (m, 1H), 7.26 – 7.12 (m, 3H), 7.11 – 7.03 (m, 2H), 
3.45 (d, J = 12.2 Hz, 1H), 3.30 (d, J = 12.2 Hz, 1H). 13C{1H} 
NMR (101 MHz, DMSO-d6): δ 168.1, 148.2, 139.9, 136.5, 
132.8, 130.6, 129.1, 128.9, 128.8, 128.4, 127.0, 125.9, 123.8, 
123.0, 73.1, 34.1.
3-(butanethio)-3-phenylisoindolin-1-one (6i). To a 4 mL vial 
was added 3-hydroxy-3-phenylisoindolin-1-one (100 mg, 0.44 
mmol), Ca(NTf2)2 (3 mg, 0.0044 mmol) and nBu4NPF6 (1.7 mg, 
0.0044 mmol) in DCE (2 mL) at 80 ºC. The reaction was stirred 
for 5 minutes and butanethiol (48 mg, 0.53 mmol) was added in 
a single portion and stirred at 80 ºC for 15 minutes. Once TLC 
analysis indicated conversion to the product, the product was 
concentrated and purified by flash column chromatography 
(1:1, EtOAc:Hex) to afford a yellow oil which solidified upon 
standing (120 mg, 91%). RF (1:1 EtOAc/Hex) = 0.70. IR νmax 
(cm-1): 3185, 3066, 2956, 1698, 1310. HRMS (ESI) m/z: 
[M+H]+ Calcd for C18H20NOS 298.1266; found 298.1259. 1H 
NMR (400 MHz, CDCl3): δ 7.98 (s, 1H), 7.83 (d, J = 7.5 Hz, 
1H), 7.77 – 7.67 (m, 2H), 7.67 – 7.53 (m, 2H), 7.45 (td, J = 7.4, 
0.8 Hz, 1H), 7.40 – 7.27 (m, 3H), 2.35 – 2.25 (m, 1H), 2.11 – 
1.98 (m, 1H), 1.45 – 1.12 (m, 4H), 0.74 (t, J = 7.2 Hz, 3H). 
13C{1H} NMR (101 MHz, CDCl3): δ 169.7, 149.3, 140.0, 132.9, 
130.3, 129.0, 128.9, 128.6, 125.8, 123.8, 123.7, 73.2, 30.7, 29.3, 
22.1, 13.6.
3-(cyclohexanethio)-3-phenylisoindolin-1-one (6j). To a 4 mL 
vial was added 3-hydroxy-3-phenylisoindolin-1-one (100 mg, 
0.44 mmol), Ca(NTf2)2 (3 mg, 0.0044 mmol) and nBu4NPF6 
(1.7 mg, 0.0044 mmol) in DCE (2 mL) at 80 ºC. The reaction 
was stirred for 5 minutes and cyclohexanethiol (77 mg, 0.66 
mmol) was added in a single portion and stirred at 80 ºC for 15 
minutes. Once TLC analysis indicated conversion to the 
product, the product was concentrated and purified by flash 
column chromatography (1:1, EtOAc:Hex) to afford a yellow 
oil which solidified upon standing (134 mg, 93%). RF (1:1 
EtOAc/Hex) = 0.52. IR νmax (cm-1): 3156, 3061, 2926, 1690, 
1464, 1312. HRMS (ESI) m/z: [M+H]+ Calcd for C20H22NOS 
324.1422; found 324.1418. 1H NMR (400 MHz, CDCl3): δ 7.83 
(d, J = 7.5 Hz, 1H), 7.75 – 7.68 (m, 3H), 7.63 (d, J = 7.7 Hz, 
1H), 7.56 (td, J = 7.6, 1.0 Hz, 1H), 7.45 (td, J = 7.5, 0.9 Hz, 
1H), 7.39 – 7.24 (m, 3H), 2.35 – 2.20 (m, 1H), 1.91 – 1.75 (m, 
1H), 1.68 – 1.55 (m, 1H), 1.55 – 1.44 (m, 1H), 1.44 – 1.28 (m, 
3H), 1.28 – 0.97 (m, 4H). 13C{1H} NMR (101 MHz, CDCl3): δ 
169.5, 149.6, 140.3, 132.8, 130.1, 128.9, 128.6, 125.8, 124.0, 
123.8, 77.5, 43.3, 35.1, 34.6, 26.0, 25.9, 25.5.
3-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-
yl)benzenethiol)-3-phenylisoindolin-1-one (6k). To a 4 mL vial 
was added 3-hydroxy-3-phenylisoindolin-1-one (50 mg, 0.22 
mmol), Ca(NTf2)2 (3 mg, 0.0022 mmol) and nBu4NPF6 (1.7 mg, 
0.0022 mmol) in DCE (1 mL) at 80 ºC. The reaction was stirred 
for 5 minutes and 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-
2-yl)benzenethiol (79 mg, 0.33 mmol) was added in a single 
portion and stirred at 80 ºC for 15 minutes. Once TLC analysis 
indicated conversion to the product, the product was 
concentrated and purified by flash column chromatography 
(1:1, EtOAc:Hex) to afford a peach solid (73 mg, 74%). RF (1:1 
EtOAc/CycHex) = 0.60. IR νmax (cm-1): 3502, 3162, 3067, 2989, 
1697, 1358. HRMS (ESI) m/z: [M+H]+ Calcd for C26H27BNO3S 
444.1805; found 444.1813. 1H NMR (400 MHz, DMSO-d6): δ 
9.88 (s, 1H), 7.89 (d, J = 7.8 Hz, 1H), 7.78 (d, J = 7.4 Hz, 2H), 
7.68 – 7.61 (m, 1H), 7.46 (t, J = 7.5 Hz, 2H), 7.38 (q, J = 8.1 
Hz, 4H), 7.30 (d, J = 7.4 Hz, 1H), 7.14 (d, J = 8.0 Hz, 2H), 1.25 
(s, 12H). 13C{1H} NMR (101 MHz, DMSO-d6): δ 167.8, 147.8, 
139.4, 135.9, 134.1, 133.1, 132.3, 130.3, 128.9, 128.8, 128.7, 
126.0, 124.1, 122.4, 84.0, 75.5, 25.0, 24.7, 24.7.
2-benzyl-3-(2-chloro-4-methylanilino)-2,3-dihydro-1H-
isoindol-1-one (8a). To a 4 mL vial was added 2-benzyl-3-
hydroxy-2,3-dihydro-isoindol-1-one (50 mg, 0.21 mmol),
Ca(NTf2)2 (13 mg, 0.021 mmol) and nBu4NPF6 (8 mg, 0.021
mmol) in DCE (1 mL) at room temperature. 2-chloro-4-
methylaniline (45 mg, 0.31 mmol) was added in a single portion 
and the reaction was stirred at 80 ºC overnight. Once TLC 
analysis indicated conversion to the product, the product was 
concentrated and purified by flash column chromatography (0 
to 2% EtOAc:DCM)  to afford the desired product as a cream 
solid (48 mg, 63%). RF (1:1 EtOAc/Hex) = 0.71. IR νmax (cm-
1): 3361, 3031, 2924, 1683, 1615, 1520. HRMS (ESI) m/z: 
[M+H]+ Calcd for C22H20ClN2O 363.1264; found. 363.1265. 1H 
NMR (400 MHz, DMSO-d6): δ 7.86 – 7.78 (m, 1H), 7.69 – 7.53 
(m, 2H), 7.46 (d, J = 7.1 Hz, 1H), 7.33 – 7.22 (m, 2H), 7.22 – 
7.17 (m, 2H), 7.09 (d, J = 1.5 Hz, 1H), 6.68 (dd, J = 8.4, 1.5 Hz, 
1H), 6.25 (d, J = 8.2 Hz, 1H), 6.12 (d, J = 8.3 Hz, 1H), 6.04 (d, 
J = 8.2 Hz, 1H), 4.87 (d, J = 15.4 Hz, 1H), 4.21 (d, J = 15.5 Hz, 
1H), 2.10 (s, 3H). 13C{1H} NMR (101 MHz, DMSO-d6): δ 
166.6, 143.9, 139.1, 137.5, 132.3, 132.1, 129.7, 129.3, 128.4, 
128.1, 128.0, 127.6, 127.1, 123.3, 122.9, 119.3, 113.8, 68.5, 
42.4, 19.6.
2-benzyl-3-(2,4-difluoroanilino)-2,3-dihydro-1H-isoindol-1-
one (8b). To a 4 mL vial was added 2-benzyl-3-hydroxy-2,3-
dihydro-isoindol-1-one (50 mg, 0.21 mmol), Ca(NTf2)2 (13 mg, 
0.021 mmol) and nBu4NPF6 (8 mg, 0.021 mmol) in DCE (1 mL) 
at room temperature. 2,4-difluoroaniline (41 mg, 0.31 mmol) 
was added in a single portion and the reaction was stirred at 80 
ºC overnight. Once TLC analysis indicated conversion to the 
product, the product was concentrated and purified by flash 
column chromatography (1:10 EtOAc:Hex)  to afford the 
desired product as a colorless oil (48 mg, 68%). RF (1:1 
EtOAc/Hex) = 0.58. IR νmax (cm-1): 3415, 2917, 1694, 1497, 
1113. HRMS (ESI) m/z: [M+H]+ Calcd for C21H17F2N2O 
351.1309; found 351.1315. . 1H NMR (400 MHz, DMSO-d6): δ 
7.94 – 7.92 (m, 1H), 7.57 – 7.53 (m, 2H), 7.47 – 7.43 (m, 1H), 
7.32 – 7.24 (m, 3H), 7.21 – 7.19 (m, 2H), 6.79 (ddd, J = 11.3, 
8.4, 2.8 Hz, 1H), 6.56 (ddd, J = 4.3, 3.5, 1.6 Hz, 1H), 6.27 (td, 
J = 9.3, 5.4 Hz, 1H), 5.71 (s, 1H), 5.26 (d, J = 15.1 Hz, 1H), 
4.29 – 4.11 (m, 2H). 13C{1H} NMR (101 MHz, DMSO-d6): δ  
167.7, 143.2, 137.0, 132.4, 132.1, 129.8, 129.6 (dd, J = 11.4, 





























































2.9 Hz), 128.9, 128.2, 127.8, 124.00, 123.1, 115.3 (dd, J = 8.9, 
3.4 Hz), 111.2 (d, J = 3.7 Hz), 111.0 (d, J = 3.7 Hz), 104.0 (dd, 
J = 26.4, 23.5 Hz), 68.9, 43.2.
2-benzyl-3-[2-methoxy-5-(trifluoromethyl)anilino]-2,3-
dihydro-1H-isoindol-1-one (8c). To a 4 mL vial was added 2-
benzyl-3-hydroxy-2,3-dihydro-isoindol-1-one (50 mg, 0.21
mmol), Ca(NTf2)2 (13 mg, 0.021 mmol) and nBu4NPF6 (8 mg, 
0.021 mmol) in DCE (1 mL) at room temperature. 2-methoxy-
5-(trifluoromethyl)aniline (60 mg, 0.31 mmol) was added in a 
single portion and the reaction was stirred at 80 ºC overnight. 
Once TLC analysis indicated conversion to the product, the 
product was concentrated and purified by flash column 
chromatography (0 to 5% EtOAc:DCM)  to afford the desired 
product as a light brown solid (70 mg, 81%). RF (1:20 
EtOAc/DCM) = 0.33. IR νmax (cm-1): 3415, 2917, 1694, 1497, 
1113. HRMS (ESI) m/z: [M+H]+ Calcd for C23H19F3N2O2 
413.1477; found 413.1497. 1H NMR (400 MHz, DMSO-d6): δ 
7.81 (d, J = 6.5 Hz, 1H), 7.70 – 7.52 (m, 2H), 7.48 (d, J = 6.8 
Hz, 1H), 7.28 – 7.05 (m, 5H), 6.95 – 6.82 (m, 2H), 6.44 (d, J = 
8.1 Hz, 1H), 6.21 (s, 1H), 6.12 (d, J = 8.3 Hz, 1H), 4.79 (d, J = 
15.4 Hz, 1H), 4.28 (d, J = 15.5 Hz, 1H), 3.81 (s, 3H). 13C{1H} 
NMR (101 MHz, DMSO-d6): δ 166.6, 149.6, 143.7, 137.4, 
135.2, 132.3, 132.1, 129.4, 128.2, 127.4, 126.9, 123.4, 122.9, 
114.6, 110.0, 107.5, 68.2, 55.8, 42.7.
2-benzyl-3-(cyclopropylamino)-2,3-dihydro-1H-isoindol-1-one
(8d). To a 4 mL vial was added 2-benzyl-3-hydroxy-2,3-
dihydro-isoindol-1-one (50 mg, 0.21 mmol), Ca(NTf2)2 (13 mg, 
0.021 mmol) and nBu4NPF6 (8 mg, 0.021 mmol) in DCE (1 mL) 
at room temperature. cyclopropylamine (18 mg, 0.31 mmol) 
was added in a single portion and the reaction was stirred at 80 
ºC overnight. Once TLC analysis indicated conversion to the 
product, the product was concentrated and purified by flash 
column chromatography (1:5 EtOAc:Hex, 1% NEt3) to afford 
the desired product as a colorless oil (39 mg, 67%). RF (1:5 
EtOAc/Hex) = 0.48. IR νmax (cm-1): 3415, 2917, 1694, 1497, 
1113. HRMS (ESI) m/z: [M+H]+ Calcd for C18H19N2O 
279.1497; found 279.1492. 1H NMR (400 MHz, DMSO-d6): δ 
7.88 – 7.86 (m, 1H), 7.55 – 7.46 (m, 3H), 7.33 – 7.24 (m, 5H), 
5.30 (d, J = 15.0 Hz, 1H), 5.16 (s, 1H), 4.27 (d, J = 15.0 Hz, 
1H), 2.05 – 2.00 (m, 1H), 0.39 – 0.30 (m, 2H), 0.22 – 0.08 (m, 
2H). 13C{1H}NMR (101 MHz, DMSO-d6):δ 167.8, 144.6, 
137.6, 132.5, 131.6, 129.0, 128.9, 128.3, 127.6, 123.6, 123.5, 
72.4, 43.1, 24.7, 7.6, 6.0.
2-benzyl-3-(benzylamino)-2,3-dihydro-1H-isoindol-1-one (8e).
To a 4 mL vial was added 2-benzyl-3-hydroxy-2,3-dihydro-
isoindol-1-one (50 mg, 0.21 mmol), Ca(NTf2)2 (12.5 mg, 0.021 
mmol) and nBu4NPF6 (8.1 mg, 0.021 mmol) in DCE (1 mL) at 
room temperature. benzylamine (34 mg, 0.31 mmol) was added 
in a single portion and the reaction was stirred at 80 ºC 
overnight. Once TLC analysis indicated conversion to the 
product, the product was concentrated and purified by flash 
column chromatography (1:5 EtOAc:Hex, 1% NEt3) to afford 
the desired product as a colorless oil (64 mg, 93%). RF (1:1 
EtOAc/Hex) = 0.61. IR νmax (cm-1): 3320, 3029, 2850, 1678, 
1454, 1219. HRMS (ESI) m/z: [M+H]+ Calcd for C22H21N2O 
329.1654; found 329.1652. 1H NMR (400 MHz, DMSO-d6): δ 
7.89 (d, J = 7.3 Hz, 1H), 7.57 – 7.48 (m, 3H), 7.34 – 7.21 (m, 
8H), 7.16 (d, J = 6.8 Hz, 2H), 5.34 (s, 1H), 5.19 (d, J = 15.0 Hz, 
1H), 4.34 (d, J = 15.0 Hz, 1H), 3.36 (d, J = 13.0 Hz, 1H), 3.25 
(d, J = 13.0 Hz, 1H). 13C{1H} NMR (101 MHz, DMSO-d6): δ 
168.2, 143.6, 140.0, 137.8, 133.2, 132.3, 129.6, 129.3, 128.8, 
128.7, 128.5, 128.1, 127.6, 124.0, 123.6, 72.7, 45.9, 43.6.
Benzyl (2-benzyl-3-oxo-2,3-dihydro-1H-isoindol-1-
yl)carbamate (12a). To a 4 mL vial was added 2-benzyl-3-
hydroxy-2,3-dihydro-isoindol-1-one (50 mg, 0.21 mM), 
Ca(NTf2)2 (1.3 mg, 0.0021 mmol) and nBu4NPF6 (0.8 mg, 
0.0021 mmol) in DCE (1 mL) at 80 ºC. The reaction was stirred 
for 1 minute and benzylcarbamate (35 mg, 0.23 mmol) was 
added in a single portion and stirred at 80 ºC for 15 minutes. 
Once TLC analysis indicated conversion to the product, the 
product was concentrated and purified by flash column 
chromatography (1:1, EtOAc:Hex) followed by trituration with 
Et2O to afford the product as a white solid (70 mg, 90%). RF 
(1:5 EtOAc/DCM) = 0.74. IR νmax (cm-1): 3306, 3034, 2925, 
1687, 1528, 1425. . HRMS (ESI) m/z: [M+H]+ Calcd for 
C23H21N2O3 373.1552 found 373.1552. 1H NMR (400 MHz, 
DMSO-d6): δ 8.23 (d, J = 9.2 Hz, 1H), 7.73 (d, J = 7.4 Hz, 1H), 
7.64 (t, J = 7.3 Hz, 1H), 7.55 (dd, J = 13.5, 7.3 Hz, 2H), 7.46 – 
7.20 (m, 10H), 6.09 (d, J = 9.1 Hz, 1H), 5.20 – 4.98 (m, 2H), 
4.80 (d, J = 15.4 Hz, 1H), 4.32 (d, J = 15.4 Hz, 1H). 13C{1H} 
NMR (101 MHz, DMSO-d6): δ 166.5, 156.3, 143.0, 137.6, 
136.7, 132.3, 131.7, 129.4, 128.4, 128.0, 127.8, 127.7, 127.2, 
123.5, 122.7, 65.9, 65.8, 43.1
tert-butyl (2-benzyl-3-oxo-2,3-dihydro-1H-isoindol-1-
yl)carbamate (12b). To a 4 mL vial was added 2-benzyl-3-
hydroxy-2,3-dihydro-isoindol-1-one (50 mg, 0.21 mmol), 
Ca(NTf2)2 (1.3 mg, 0.0021 mmol) and nBu4NPF6 (0.8 mg, 
0.0021 mmol) in DCE (1 mL) at 80 ºC. The reaction was stirred 
for 1 minute and tert-butylcarbamate (29 mg, 0.25 mmol) was 
added in a single portion and stirred at 80 ºC for 15 minutes. 
Once TLC analysis indicated conversion to the product, the 
product was concentrated and purified by flash column 
chromatography (1:1 EtOAC:Hex) followed by trituration with 
Et2O to afford the product as a white solid (61 mg, 86%). RF 
(1:1 EtOAc/Hex) = 0.50. IR νmax (cm-1): 3270, 2985, 2929, 
1712, 1684, 1519. HRMS (ESI) m/z: [M+H]+ Calcd for 
C20H23N2O2 339.1709; found 339.1696. 1H NMR (400 MHz, 
DMSO-d6): δ 7.81 (d, J = 9.1 Hz, 1H), 7.71 (d, J = 7.4 Hz, 1H), 
7.63 (t, J = 7.2 Hz, 1H), 7.58 – 7.46 (m, 1H), 7.39 – 7.18 (m, 
1H), 6.03 (d, J = 9.0 Hz, 1H), 4.83 (d, J = 15.3 Hz, 1H), 4.28 
(d, J = 15.5 Hz, 1H), 1.39 (s, 1H). 13C{1H} NMR (101 MHz, 
DMSO-d6): δ 166.6, 155.6, 143.3, 137.8, 132.2, 131.7, 129.3, 
128.5, 127.6, 127.1, 123.5, 122.6, 79.0, 65.5, 43.1, 28.1.
N-(2-benzyl-3-oxo-2,3-dihydro-1H-isoindol-1-yl)benzamide 
(12c). To a 4 mL vial was added 2-benzyl-3-hydroxy-2,3-
dihydro-isoindol-1-one (50 mg, 0.21 mmol) Ca(NTf2)2 (6.3 mg, 
0.0104 mmol) and nBu4NPF6 (4 mg, 0.0104 mmol) in DCE (1 
mL) at 80 ºC. The reaction was stirred for 1 minute and 
benzamide (38 mg, 0.3 mmol) was added in a single portion and 
stirred at 80 ºC for 15 minutes. Once TLC analysis indicated 
conversion to the product, the product was concentrated and 
purified by flash column chromatography (1:1, EtOAc:Hex) to 
afford a white solid (68 mg, 95%). RF (1:1 EtOAc/Hex) = 0.41. 
IR νmax (cm-1): 3548, 3278, 3031, 2933, 1705, 1270. HRMS 
(ESI) m/z: [M+H]+ Calcd for C22H19N2O2 343.1447; found 
343.1441. 1H NMR (400 MHz, DMSO-d6): δ 9.20 (d, J = 8.9 
Hz, 1H), 7.82 (d, J = 7.6 Hz, 2H), 7.78 (d, J = 7.3 Hz, 1H), 7.71 
– 7.51 (m, 4H), 7.45 (t, J = 7.6 Hz, 2H), 7.38 – 7.14 (m, 5H),
6.61 (d, J = 8.9 Hz, 1H), 4.85 (d, J = 15.4 Hz, 1H), 4.37 (d, J =
15.4 Hz, 1H). 13C{1H} NMR (101 MHz, DMSO-d6): δ 167.3,





























































166.9, 143, 137.7, 133.3, 132.3, 131.9, 131.9, 129.4, 128.5, 
128.3, 127.7, 127.6, 127.2, 123.6, 122.8, 63.8, 43.2.
2-benzyl-3-(2-oxo-1,3-oxazolidin-3-yl)-2,3-dihydro-1H-
isoindol-1-one (12d). To a 4 mL vial was added 2-benzyl-3-
hydroxy-2,3-dihydro-isoindol-1-one (50 mg, 0.21 mmol),
Ca(NTf2)2 (1.3 mg, 0.0021 mmol) and nBu4NPF6 (1 mg, 0.0021
mmol) in DCE (1 mL) at 80 ºC. The reaction was stirred for 1 
minute and 2-oxazolidinone (27 mg, 0.31 mmol) was added in 
a single portion and stirred at 80 ºC for 15 minutes. Once TLC 
analysis indicated conversion to the product, the product was 
concentrated and purified by flash column chromatography 
(1:9, EtOAc:DCM) to afford a white semi-solid (49 mg, 76%). 
RF (1:5 EtOAc/DCM) = 0.64. IR νmax (cm-1): 2972, 1755, 1701, 
1404, 1215. HRMS (ESI) m/z: [M+H]+ Calcd for C18H17N2O3 
309.1239; found 309.1246.  1H NMR (400 MHz, CDCl3): δ 7.91 
(d, J = 6.9 Hz, 1H), 7.64 – 7.53 (m, 2H), 7.46 (d, J = 6.9 Hz, 
2H), 7.41 (d, J = 7.2 Hz, 1H), 7.38 – 7.27 (m, 3H), 6.42 (s, 1H), 
4.96 (d, J = 14.7 Hz, 1H), 4.47 (d, J = 14.7 Hz, 1H), 4.06 (td, J 
= 9.0, 6.5 Hz, 1H), 3.53 (td, J = 9.0, 7.2 Hz, 1H), 2.75 (dd, J = 
15.9, 8.8 Hz, 1H), 2.54 (td, J = 9.0, 6.5 Hz, 1H). 13C{1H} NMR 
(101 MHz, CDCl3): δ 167.5, 158.2, 139.7, 137.4, 132.7, 132.4, 
130.3, 128.9, 128.8, 128.0, 124.3, 123.0, 68.7, 62.2, 45.1, 38.8.
N-(2-benzyl-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-4-
methylbenzene-1-sulfonamide (14a). To a 4 mL vial was added 
2-benzyl-3-hydroxy-2,3-dihydro-isoindol-1-one (50 mg, 0.21 
mmol), Ca(NTf2)2 (6.3 mg, 0.0104 mmol) and nBu4NPF6 (4 mg, 
0.0104 mmol) in DCE (1 mL) at 80 ºC. The reaction was stirred 
for 1 minute and p-toluenesulfonamide (36 mg, 0.21 mmol) was 
added in a single portion and stirred at 80 ºC overnight. Once 
TLC analysis indicated conversion to the product, hexane (2 
mL) was added and the product was collected by filtration as a 
white solid (68 mg, 85%). RF (1:5 EtOAc/DCM) = 0.57. IR νmax 
(cm-1): 3125, 2935, 2884, 1674, 1495, 1162. HRMS (ESI) m/z: 
[M+H]+ Calcd for C22H21N2O3S 393.1273; found 393.1276. 1H 
NMR (400 MHz, DMSO-d6): δ 8.94 (d, J = 8.8 Hz, 1H), 7.72 
(dd, J = 25.2, 6.9 Hz, 3H), 7.58 – 7.46 (m, 2H), 7.43 (d, J = 7.9 
Hz, 2H), 7.35 – 7.20 (m, 3H), 7.16 (d, J = 7.2 Hz, 2H), 6.73 (d, 
J = 6.2 Hz, 1H), 5.78 (d, J = 8.7 Hz, 1H), 4.82 (d, J = 15.6 Hz, 
1H), 4.22 (d, J = 15.5 Hz, 1H), 2.44 (s, 3H). 13C{1H} NMR (101 
MHz, DMSO-d6): δ 166.3, 143.3, 142.7, 139.0, 137.3, 132.3, 
131.2, 123.0, 129.7, 128.4, 127.50, 127.1, 126.4, 123.1, 122.8, 
67.6, 42.3, 21.1.
N-(2-benzyl-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-4-
methoxybenzene-1-sulfonamide (14b). To a 4 mL vial was 
added 2-benzyl-3-hydroxy-2,3-dihydro-isoindol-1-one (50 mg, 
0.21 mmol), Ca(NTf2)2 (6.27 mg, 0.0104 mmol) and nBu4NPF6 
(4.05 mg, 0.0104 mmol) in DCE (1 mL) at 80 ºC. The reaction 
was stirred for 1 minute and 4-methoxybenezenesulfonamide
(39 mg, 0.21 mmol) was added in a single portion and stirred at 
80 ºC overnight. Once TLC analysis indicated conversion to the 
product, hexane (2 mL) was added and the product was 
collected by filtration as a white solid (78 mg, 91%). RF (1:5 
EtOAc/DCM) = 0.30. IR νmax (cm-1): 3130, 2929, 2843, 1677, 
1594, 1495. HRMS (ESI) m/z: [M+H]+ Calcd for C22H21N2O4S 
409.1222; found 409.1227. 1H NMR (400 MHz, DMSO-d6):δ 
8.97 – 8.76 (m, 1H), 7.80 (d, J = 8.5 Hz, 2H), 7.70 (s, 1H), 7.57 
– 7.47 (m, 2H), 7.35 – 7.09 (m, 7H), 6.77 (s, 1H), 5.86 – 5.65
(m, 1H), 4.82 (d, J = 15.6 Hz, 1H), 4.24 (d, J = 15.5 Hz, 1H),
3.87 (s, 3H). 13C{1H} NMR (101 MHz, DMSO-d6): δ 166.3,
162.5, 142.8, 137.4, 133.5, 132.3, 131.2, 129.7, 128.6, 128.4,
127.5, 127.1, 123.2, 122.8, 114.6, 67.5, 55.8, 42.3.
N-(2-benzyl-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-2-
(trifluoromethoxy)benzene-1-sulfonamide (14c). To a 4 mL vial 
was added 2-benzyl-3-hydroxy-2,3-dihydro-isoindol-1-one (50 
mg, 0.21 mmol), Ca(NTf2)2 (6.2 mg, 0.0104 mmol) and 
nBu4NPF6 (4 mg, 0.0104 mmol) in DCE (1 mL) at 80 ºC. The 
reaction was stirred for 1 minute and 2-
(trifluoromethoxy)benezenesulfonamide (55 mg, 0.23 mmol) 
was added in a single portion and stirred at 80 ºC overnight. 
Once TLC analysis indicated conversion to the product, hexane 
(2 mL) was added and the product was collected by filtration as 
a white solid (75 mg, 78%). RF (1:5 EtOAc/DCM) = 0.56. IR 
νmax (cm-1): 3106, 3063, 1687, 1592, 1444, 1163. HRMS (ESI) 
m/z: [M+H]+ Calcd for C22H18F3N2O4S 463.0939; found 
463.0930. 1H NMR (400 MHz, DMSO-d6): δ 9.28 (d, J = 8.8 
Hz, 1H), 8.03 – 7.81 (m, 2H), 7.80 – 7.61 (m, 2H), 7.61 – 7.46 
(m, 3H), 7.42 – 7.19 (m, 3H), 7.12 (d, J = 6.8 Hz, 2H), 7.06 – 
6.88 (m, 1H), 5.79 (d, J = 8.7 Hz, 1H), 4.90 (d, J = 15.6 Hz, 
1H), 4.17 (d, J = 15.6 Hz, 1H). 13C{1H} NMR (101 MHz, 
DMSO-d6): δ 166.4, 144.9, 142.5, 137.1, 135.5, 133.6, 132.4, 
131.3, 130.1, 129.8, 128.5, 127.8, 127.3, 127.2, 123.0, 122.9, 
121.1, 67.5, 42.2.
N-(2-benzyl-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-3-
chlorobenzene-1-sulfonamide (14d). To a 4 mL vial was added 
2-benzyl-3-hydroxy-2,3-dihydro-isoindol-1-one (50 mg, 0.21 
mmol), Ca(NTf2)2 (6.3 mg, 0.0104 mmol) and nBu4NPF6 (4 mg, 
0.0104 mmol) in DCE (1 mL) at 80 ºC. The reaction was stirred 
for 1 minute and 3-chloro-benezenesulfonamide (44 mg, 0.23 
mmol) was added in a single portion and stirred at 80 ºC for 2h. 
Once TLC analysis indicated conversion to the product, hexane 
(2 mL) was added and the product was collected by filtration as 
a white solid (65 mg, 75%). RF (1:5 EtOAc/DCM) = 0.60. IR 
νmax (cm-1): 3181, 3056, 1687, 1494, 1468, 1157. HRMS (ESI) 
m/z: [M+H]+ Calcd for C21H18ClN2O3S 413.0727; found 
413.0727. 1H NMR (400 MHz, DMSO-d6): δ 9.19 (d, J = 8.7 
Hz, 1H), 7.89 – 7.78 (m, 3H), 7.76 – 7.64 (m, 2H), 7.53 (p, J = 
8.1 Hz, 2H), 7.36 – 7.22 (m, 3H), 7.18 (d, J = 7.3 Hz, 2H), 6.76 
(d, J = 6.2 Hz, 1H), 5.90 (d, J = 8.7 Hz, 1H), 4.83 (d, J = 15.6 
Hz, 1H), 4.24 (d, J = 15.6 Hz, 1H). 13C{1H} NMR (101 MHz, 
DMSO-d6): δ 166.3, 143.7, 142.4, 137.2, 134.1, 133.0, 132.3, 
131.9, 131.2, 129.8, 128.5, 127.5, 127.2, 126.1, 125.0, 123.2, 
122.9, 67.7, 42.7.
N-(2-benzyl-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-3-
fluorobenzene-1-sulfonamide (14e). To a 4 mL vial was added 
2-benzyl-3-hydroxy-2,3-dihydro-isoindol-1-one (50 mg, 0.21 
mmol), Ca(NTf2)2 (6.3 mg, 0.0104 mmol) and nBu4NPF6 (4 mg, 
0.0104 mmol) in DCE (1 mL) at 80 ºC. The reaction was stirred 
for 1 minute and 3-fluorobenezenesulfonamide (40 mg, 0.23 
mmol) was added in a single portion and stirred at 80 ºC 
overnight. Once TLC analysis indicated conversion to the 
product, hexane (2 mL) was added and the product was 
collected by filtration as a white solid (65 mg, 68%). RF (1:5 
EtOAc/DCM) = 0.60. IR νmax (cm-1): 3197, 3072, 2936, 1685, 
1494, 1345. HRMS (ESI) m/z: [M+H]+ Calcd for 
C21H18FN2O3S 397.1022; found 397.1023. 1H NMR (400 MHz, 





























































DMSO-d6): δ 9.17 (d, J = 8.8 Hz, 1H), 7.80 – 7.57 (m, 5H), 7.52 
(p, J = 7.7 Hz, 2H), 7.35 – 7.14 (m, 5H), 6.73 (d, J = 6.0 Hz, 
1H), 5.90 (d, J = 8.8 Hz, 1H), 4.83 (d, J = 15.6 Hz, 1H), 4.25 
(d, J = 15.6 Hz, 1H). 13C{1H} NMR (101 MHz, DMSO-d6): δ 
166.3, 163.1, 160.6, 143.9 (d, J = 6.6 Hz), 142.5, 137.3, 132.4, 
132.1 (d, J = 7.9 Hz), 131.2, 129.8, 128.5, 127.5, 127.1, 123.1, 
122.9, 122.6, 120.2 (d, J = 21.1 Hz), 113.6 (d, J = 24.5 Hz), 
67.7, 42.5
N-(2-benzyl-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-2,4-
difluorobenzene-1-sulfonamide (14f). To a 4 mL vial was added 
2-benzyl-3-hydroxy-2,3-dihydro-isoindol-1-one (43 mg, 0.18 
mmol), Ca(NTf2)2 (6 mg, 0.00906 mmol) and nBu4NPF6 (4 mg, 
0.0906 mmol) in DCE (1 mL) at 80 ºC. The reaction was stirred 
for 1 minute and 2,4-difluorobenezenesulfonamide (35 mg, 
0.18 mmol) was added in a single portion and stirred at 80 ºC 
overnight. Once TLC analysis indicated conversion to the 
product, hexane (2 mL) was added and the product was 
collected by filtration as a white solid (45 mg, 60%). RF (1:5 
EtOAc/DCM) = 0.69. IR νmax (cm-1): 3541, 3265, 3091, 1681, 
1601, 1418. HRMS (ESI) m/z: [M+H]+ Calcd for C21H17F-
2N2O3S 415.0928; found 415.0924. 1H NMR (400 MHz, 
DMSO-d6): δ 9.43 (d, J = 8.7 Hz, 1H), 7.80 (dd, J = 14.9, 8.5 
Hz, 1H), 7.76 – 7.67 (m, 1H), 7.66 – 7.50 (m, 3H), 7.35 – 7.20 
(m, 5H), 7.15 (d, J = 6.9 Hz, 2H), 7.06 (d, J = 6.9 Hz, 1H), 5.79 
(d, J = 8.6 Hz, 1H), 4.89 (d, J = 15.8 Hz, 1H), 4.23 (d, J = 15.8 
Hz, 1H). 13C{1H} NMR (101 MHz, DMSO-d6): δ 166.5, 166.5, 
164.0 (d, J = 11.6 Hz), 160.1 (d, J = 13.6 Hz), 157.5 (d, J = 13.5 
Hz), 142.4, 137.1, 132.5, 131.4 (d, J = 10.8 Hz), 131.3, 129.8, 
128.5, 127.2, 127.2, 126.2 (dd, J = 13.9, 3.4 Hz), 123.0 (d, J = 
24.2 Hz), 112.4 (d, J = 22.7 Hz), 67.5, 42.3.
N-(2-benzyl-3-oxo-2,3-dihydro-1H-isoindol-1-yl)thiophene-2-
sulfonamide (14g). To a 4 mL vial was added 2-benzyl-3-
hydroxy-2,3-dihydro-isoindol-1-one (50 mg, 0.21 mmol), 
Ca(NTf2)2 (6.3 mg, 0.0104 mmol) and nBu4NPF6 (4 mg, 0.0104 
mmol) in DCE (1 mL) at 80 ºC. The reaction was stirred for 1 
minute and 2-thiophenesulfonamide (38 mg, 0.23 mmol) was 
added in a single portion and stirred at 80 ºC overnight. Once 
TLC analysis indicated conversion to the product, hexane (2 
mL) was added and the product was collected by filtration as a 
white solid (62 mg, 77%). RF (1:5 EtOAc/DCM) = 0.58. IR νmax 
(cm-1): 3345, 3105, 2894, 1664, 1467, 1198. . HRMS (ESI) m/z: 
[M+H]+ Calcd for C19H17N2O3S2 385.0681; found 385.0680. 1H 
NMR (400 MHz, DMSO-d6): δ 9.25 (d, J = 8.8 Hz, 1H), 8.04 
(d, J = 4.8 Hz, 1H), 7.75 – 7.60 (m, 2H), 7.56 – 7.45 (m, 2H), 
7.37 – 7.17 (m, 6H), 6.83 – 6.61 (m, 1H), 5.84 (d, J = 8.8 Hz, 
1H), 4.85 (d, J = 15.5 Hz, 1H), 4.29 (d, J = 15.6 Hz, 1H). 
13C{1H} NMR (101 MHz, DMSO-d6): δ 166.3, 142.7, 142.5, 
137.4, 133.4, 132.4, 132.4, 131.2, 129.8, 128.5, 128.1, 127.6, 
127.1, 123.1, 122.9, 67.7, 42.5.
N-(2-benzyl-3-oxo-2,3-dihydro-1H-isoindol-1-
yl)cyclopropanesulfonamide (14h). To a 4 mL vial was added 
2-benzyl-3-hydroxy-2,3-dihydro-isoindol-1-one (50 mg, 0.21 
mmol), Ca(NTf2)2 (6.3 mg, 0.0104 mmol) and nBu4NPF6 (4 mg, 
0.0104 mmol) in DCE (1 mL) at 80 ºC. The reaction was stirred 
for 1 minute and cyclopropanesulfonamide (28 mg, 0.23 mmol) 
was added in a single portion and stirred at 80 ºC overnight. 
Once TLC analysis indicated conversion to the product, hexane 
(2 mL) was added and the product was collected by filtration as 
a white solid (44 mg, 61%). RF (1:5 EtOAc/DCM) = 0.35. IR 
νmax (cm-1): 3387, 3277, 3125, 1671, 1470, 1295. HRMS (ESI) 
m/z: [M+H]+ Calcd for C18H19N2O3S 343.1116; found 
343.1118.. 1H NMR (400 MHz, DMSO-d6):δ 8.48 (s, 1H), 7.80 
– 7.65 (m, 3H), 7.65 – 7.54 (m, 1H), 7.42 – 7.28 (m, 4H), 7.28
– 7.17 (m, 1H), 5.88 (s, 1H), 4.92 (d, J = 15.5 Hz, 1H), 4.42 (d,
J = 15.6 Hz, 1H), 3.08 – 2.80 (m, 1H), 1.13 – 0.97 (m, 2H), 0.96
– 0.83 (m, 2H). 13C{1H} NMR (101 MHz, DMSO-d6): δ 166.3, 
143.2, 137.7, 132.4, 131.3, 129.7, 128.5, 127.7, 127.1, 124.0, 
122.7, 67.7, 42.2, 31.6, 5.6, 5.3.
Supporting Information
The Supporting Information is available free of charge on the ACS 
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